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 Drug discovery and development from marine invertebrates has been fraught with 
two key problems, namely, the variability of occurrence and limited supply. Bacteria in 
symbiosis with marine invertebrates have been shown to produce most bioactive natural 
products isolated from these organisms, and thus are central to addressing questions of 
occurrence and issues of supply. Specifically, the factors that influence symbiosis 
influence the distribution and supply of natural products. This dissertation sought to 
address these two problems through studies in symbiosis and supply of symbiotic natural 
products. 
 First, the global patterns of chemical symbiosis in marine ascidians, a group of 
highly prolific producers of natural products, were examined. Symbiosis in ascidians is 
shown to be host-specific (meaning that similar species of invertebrates contain similar 
bacterial symbionts); further, microbiomes are shown to be equally diverse regardless of 
location. Secondary metabolism was also found to be host-specific, but is more sensitive 
to biogeographical factors as evidenced by the increase in the potency of the secondary 
metabolites in tropical regions. To address the supply of rare natural products, 
heterologous expression was used to produce useful quantities of a group of symbiotic 
natural products, cyanobactins. Using metabolic engineering, a platform was developed 
to supply cyanobactins in high-titer, and its usefulness showcased in the discovery of
!novel activities of these natural products. Another facet of the supply problem is the 
substantial difficulty involved in synthesizing derivatives of natural products, which 
generally requires total chemical synthesis. On this aspect of the supply problem, the 
capacity of the cyanobactin pathway to generate unprecendented structural diversity by 
the incorporation of non-proteinogenic amino acids into this multistep, substrate-tolerant 
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Natural products variability and supply 
 Natural products (NPs) are an excellent source of bioactive lead compounds for 
drug discovery.1 Among NP producers, marine invertebrates are known for harboring 
diverse, biologically potent, and structurally complex metabolites that possess drug-like 
qualities.2 For example, of 36 marine natural products that were in the preclinical/clinical 
pipeline from 2004-2013, 30 were originally sourced from marine invertebrates.3 
However, drug discovery from marine invertebrates has been fraught with two problems, 
namely, the variability in isolation and limited supply. The isolation of a natural product 
from an organism, especially from a sessile invertebrate such as a sponge or an ascidian, 
does not guarantee that one will find the same natural products in subsequent collections.4 
Central to these challenges is the role of symbiotic bacteria in the production of marine 
invertebrate-derived natural products. 5-7Specifically, symbiotic bacteria are central to 
chemical symbiosis, NP variability, and, as a result, to the supply of NPs. This 
dissertation addresses these two problems, the distribution and supply of symbiotic 
natural products.  
 
Symbiosis driven variability in natural products 
 The following examples illustrate the influence of symbiosis on the distribution 
and variability of natural products from three invertebrate phyla: bryozoans, sponges, and 
ascidians. The identification of the symbiont producers is described in each case, as well 
as the factors that influence invertebrate-microbe symbiosis resulting in the sporadic 
occurrence of natural products. These studies emphasize the unappreciated role of cryptic 
host speciation, symbiont genetics, and geography in the production of compounds. 
! "!
Lastly, these individual cases, among others, prompted us to examine the global 
distribution of ascidian microbial symbionts, which is the topic of the first part of my 
research. 
 
Candidatus Endobugula sertula and the bryostatins 
 One of the most well-rounded studies in this field is the investigation of the 
chemical symbiosis between the bryozoan Bugula neritina and its symbiont Candidatus 
Endobugula sertula. The bryozoan B. neritina is a cosmopolitan species that is widely 
distributed in the temperate and tropical ocean regions. 8,9 It is the source of the 
bryostatins, powerful protein kinase C (PKC) modulators that have been extensively 
investigated for their anticancer, antiviral, and neuroactive properties. 9 Limited and 
variable isolation from the bryozoans prompted a series of studies on the biosynthetic 
origin and ecology of bryostatins, with the goal of finding alternative routes of supplying 
these high-demand molecules.  
 The structure of bryostatins suggests a microbial origin, specifically via 
polyketide synthase (PKS) machinery followed by multiple tailoring steps. Indeed, an 
uncultured gamma-proteobacterium associated with larvae of the bryostatin-producing B. 
neritina was identified and named Candidatus Endobugula sertula. 10 11 The same 
bacterium was found to harbor a set of biosynthetic genes consistent with biosynthetic 
hypotheses as to the origin of of bryostatins. 12,13 Subsequent studies strongly supported 
the hypothesis that Ca. E. sertula produces bryostatins. 14 Final proof will await attempts 
to express the bryostatin gene cluster in a heterologous host, which have not been 
successful to date.  Meanwhile, efforts continue to further our understanding of the 
! "!
genetics of the Ca. E. sertula symbiont. Early studies on the isolation of bryostatins 
indicated a variable distribution in B. neritina species. 15 Identifying the genetic basis of 
bryostatins was critical to further progress in the understanding of the distribution of 
these molecules. Haygood and Davidson (1999) first showed that the B. neritina 
populations along the coast of California are composed of sibling species. 16 Type D 
(found in deep waters initially) and type S (found in shallow waters) differed by 8% in 
their mitochondrial CO1 sequences. Both harbored Ca. E. sertula symbionts that differed 
in their 16S rRNA gene sequences, and the bryostatin chemistry differed in each type of 
B. neritina. Subsequently, cryptic species of B. neritina were also identified from the 
western Atlantic range, 8 and a series of studies have highlighted the influence of 
geography in the distribution of B. neritina and bryostatin production. In these studies, 
Cape Haterras, a known biogeographical divide, was used as the reference point in the 
sampling of B. neritina. Another cryptic species of B. neritina, type N, generally inhabits 
the northern Atlantic ranges and does not harbor Ca. E. sertula symbionts. 8  This species 
lacks bryostatins, consistent with a producer role for Ca. E. sertula. Subspecies Type S of 
B. neritina, similar to the California species, is concentrated in southern areas relative to 
Cape Haterras and contains both Ca. E. sertula symbionts as well as bryostatins. The 
presence or absence of symbionts was therefore thought to explain completely the 
separation between species. Recently, however, more detailed collections have shown 
that the boundary of N and S species is less distinct than previously thought. 17,18 
Although there is a heavy distribution of N type north of Cape Haterras, some N type 
species were also found south of the Cape and vice versa. Despite this apparent mixing of 
host species, the Ca. E. sertula symbionts remained geographically restricted to the south, 
! "!
regardless of the species of B. neritina. 18 This implies that bryostatin production might 
be strongly influenced by geography. Higher selection pressure in the southern warmer 
waters may lead to acquisition of Ca. E. sertula symbionts that can provide chemical 
defense. These studies demonstrate the interplay between different factors controlling the 
production of bryostatins. Cryptic speciation in B. neritina partly explains the presence 
and absence of symbionts and compounds, while the host-specificity of symbionts to 
these cryptic species of B. neritina appears to explain the variation between different 
bryostatin derivatives. Finally, the local environment may also play a role, presumably 
via natural selection, in determining the presence or absence of symbiotic natural product 
producers.  Further widespread studies of the bryostatins, B. neritina, and Ca. E. sertula 
will be needed to attain a complete picture of bryostatin occurence and variation.  
 
Prochloron didemni and the cyanobactins 
 Ascidians from the family Didemnidae are among the most chemically prolific 
groups of marine invertebrates. 2,7 Among other natural products, they produce a family 
of small cyclic peptides, known as cyanobactins. 19 Genome analysis of the obligate 
cyanobacterial symbiont of the ascidian Lissoclinum patella, Prochloron didemni, 
identified the biosynthetic cluster for cyanobactins, which was found to involve a 
ribosomal mode of biosynthesis, in which a precursor peptide is posttranslationally 
modified to give bioactive structures. 20 This mode of biosynthesis is now recognized as 
widespread, and a large class of natural products has been assigned to the growing family 
of ribosomally synthesized and posttranslationally modified peptides (RiPPs). 21 
 The cyanobactins are to date the most biotechnologically developed group among 
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natural products from uncultured symbiotic bacteria. One important milestone in the 
development of cyanobactins as a platform for drug discovery was the demonstration, 
coincident with the discovery of their biosynthetic origins, that they could be 
heterologously expressed in E. coli.  20 Also important was the discovery of the 
tremendous flexibility of the cyanobactin pathway. 22 This latter discovery was largely 
enabled by an in-depth understanding of their distribution and variation in Nature. 22,23 
Diverse families of cyanobactins had been isolated from different species of didemnid 
ascidians since the 1980s. 19,24-27 Structural overlaps between these families led to the 
hypothesis that much of cyanobactin chemical diversity can be traced to hypervariability 
in precursor peptides. 22 Indeed, analyses of cyanobactin pathways from didemnid 
ascidians across the tropical Pacific showed that the sequences are virtually identical 
except for regions that directly encode the cyanobactin backbone.22  In some cases, 
recombination of pathways leads to altered patters of posttranslational modifications, but 
even in such cases, precursor peptides from different pathways can be mixed and 
matched in vitro and in vivo. 23 Producing artificial libraries of cyanobactins would 
therefore only require minimal manipulation of precursor peptides, without any 
engineering of modifying enzymes. This in-depth knowledge of the conserved genetic 
architecture of cyanobactin pathways also accelerated the discovery of cyanobactin 
derivatives by purely genetic approaches. 28 
 Cyanobactin families are also variably distributed in didemnid ascidians. For 
example, trunkamides, patellins, patellamides, and lissoclinamides are often found in 
different combinations in L. patella ascidians. 22,29,30 To examine this question, three 
genomes of Prochloron didemni were sequenced and compared.29 This analysis revealed 
! "!
that the Prochloron didemni strains were largely identical except in regions that encoded 
secondary metabolites.  Subsequently, 24 Prochloron didemni strains from different L. 
patella samples across the tropical Pacific were analyzed at specific loci as well as for 
secondary metabolite composition.  No apparent distribution patterns could be discerned 
however. It was hypothesized that the sporadic variation in the pathways and metabolites 
is ecologically relevant for Prochloron-L. patella symbiosis. Specifically, the presence of 
different pathways in different ascidians allows access to the suite of cyanobactins as 
needed.  
 A finer look at the L. patella phylogeny later revealed a previously unrecognized 
distribution. 31 Specifically, L. patella samples collected from the vast tropical Pacific 
were identified to derive from cryptic speciation events, varying by 5-10% in their 
mtCO1 sequences.  From this analysis, the phylogeny of L. patella could be used to 
predict the distribution of cyanobactins, while the Prochloron symbiont was 99% 
identical in all cases. Thus, in an echo of the bryostatin work described above, host 
cryptic speciation was found to be a key driving force of the distribution of cyanobactins. 
A broader sampling of L. patella samples will be needed to show if this ‘host control’ 
phenomenon is widespread and what other factors determine this symbiosis, for example 
host-factors that allow for recognition of specific Prochloron strains, or perhaps vertical 
transmission of symbionts. An improved understanding of the distribution of metabolites 
in L. patella across time and space might help improve our understanding of the 




Candidatus Entotheonella sp. and a suite of peptides and polyketides 
 The marine sponges from the family Theonellidae are another group of marine 
invertebrates that have been studied for their structurally complex and bioactive NPs. 32 
Most of these molecules are complex polyketides including the swinholides and 
discodermolides, as well as peptides such as keramamides, polytheonamides, theopalau -
amides, or hybrid PKS-NRPS-derived molecules such as the calyculins, onnamides, and 
theopederins. 32-35 The microbial origin of these metabolites has been proposed early on. 
Indeed, microscopy 36,37 and later biosynthetic studies confirmed this hypothesis. 38,39  
 Perhaps the earliest attempt to implicate symbiotic bacteria in the biosynthesis of 
sponge-derived metabolites was from the work of Bewley et al. in the mid-1990s. 36 
Separation of microbial cells by differential centrifugation and subsequent chemical 
analysis showed that different microbial fractions contained different metabolites. For 
example, a fraction enriched in unicellular bacteria contained swinholides, while the 
fraction containing filamentous bacteria contained cyclic peptides of the theopalauamide 
family. In 2000, Schmidt et al. described the filamentous bacteria as a novel !-
proteobacteria, named Candidatus Entotheonella palauensis. 40 In this key study, the 
relationship of chemistry to the symbiont genotype was first proposed. More than a 
decade later, using a combination of single cell genomics and metagenomics, Wilson et 
al. confirmed that the Ca. Entotheonella species previously identified by Schmidt et al. 
are in fact the producers of most Theonella swinhoei-derived natural products. 41 
Different strains of Ca. Entotheonella, produce different types of NPs present in the same 
T. swinhoei sample. Ca. Entotheonella species have also been described from other 
Theonellid sponges, where they are responsible for making large PKS-NRPS 
! "!
compounds.42 
 It is becoming apparent that Ca. Entotheonella strains are diverse and widespread 
among sponges. In particular, a PCR survey showed that Ca. Entotheonella strains are 
present in different sponges outside the Theonillidae and also collected from different 
locations. 41 No apparent patterns of distribution have been identified so far. It is clear, 
however, that symbiosis with different strains lead to the isolation of different 
compounds in sponges. Studies on the distribution, host-specificity, and chemistry of Ca. 
Entoheonella will be critical to advance our understanding of their distribution and to 
facilitate exploiting their potential in drug discovery.  
 
A global view of chemical symbiosis 
 The specific cases above emphasize the roles of symbiotic bacteria in the 
variability and distribution of natural products. However, they only represent a small 
subset of marine natural products. The first part of my thesis addresses this problem by 
examining global patterns in the distribution of chemical symbiosis that could guide 
natural products discovery. We focused on ascidians, examining the specificity, diversity, 
and stability of the microbiomes and secondary metabolism across hosts, geography, and 
time. We hypothesized that in the tropical regions where there is a higher degree of 
predation and competition, the selective pressure to survive leads to acquisition of more 
symbionts that could aid with the host’ fitness (e.g., chemical defense) and therefore 




Supply of symbiotic natural products 
 Natural products that are produced within the context of a symbiotic relationship 
are often potent because they are evolutionarily refined to interact with relevant 
biological targets. Consequently, they are often produced in limited amounts in the 
animals. The bryostatins described above are an excellent example of such compounds. 
The amount of bryostatins that can be isolated ranges from 10-5 to 10-7 wt% of the animal 
colony (18 grams from 14 tons of B. neritina in one example). 9 The same is true for L. 
patella metabolites, the patellazoles, which are products of the endosymbiont, Ca. 
endolissoclinum patella. 43 The patellazoles are highly cytotoxic, with an IC50 of 332 pM 
in cell assays. They are isolated at 0.08% dry weight of the ascidian and are sparsely 
found, severely hampering their development.   
 Another barrier in the supply of NPs from symbiotic bacteria is the inability to 
cultivate the producing symbionts. Symbiotic bacteria in established relationships with 
their host often lose functions that are required for independent lifestyles outside the 
hosts. In extreme cases, the genome of symbiotic bacteria is degraded over time, retaining 
only the genes that are relevant to the symbiosis such as the secondary metabolic genes, 
while depending on the host for the rest of its metabolic needs. 44 
 Chemical synthesis is often the next step in supplying the natural products, 
especially those that are highly sought for their bioactivities. However, there are obvious 
drawbacks to total chemical synthesis. Natural products are structurally complex, often 
containing multiple chiral centers, and often require lengthy synthetic routes, thus posing 
a significant barrier to achieving a practical supply. 45 The total synthesis of bryostatins, 
for example, was completed in 79 steps in 1990s, and it was not until recently (2011) that 
! ""!
several research groups achieved the total synthesis with 36 to 43 steps. 46,47 
 Heterologous expression of biosynthetic pathways in genetically tractable hosts 
such as E. coli is one of the most promising alternatives to symbiotic NP supply. 48 49 
Although not without challenges, heterologous expression offers many advantages over 
total chemical synthesis and other complementary approaches such as aquaculture. 50 
Once optimized, natural products can be supplied from scaled fermentations without the 
need for multiple reactions and in between purification steps required of total synthesis. 
In the second part of my dissertation, we used heterologous expression to address the 
supply problem in the symbiotic NPs, the cyanobactins.  
 
 Metabolic engineering and fermentation strategies for NP supply 
 Tools and strategies for the metabolic engineering of natural products expressions 
in heterologous hosts are becoming increasingly available. 51-53 Some rational techniques 
involve increasing precursor supply, overexpression of bottleneck enzymes in the 
pathways, improving regulation of gene expression, and channeling intermediates, 
precursors into desired pathways. 53 These, in tandem with empirical approaches such as 
optimization of fermentation conditions, media, additives, cofactors, and other primary 
metabolites, have been used for the improved supply of natural products in vivo. 54,55  
 Increasing the precursor supply has been employed in several pathways, including 
polyketides, terpenoids, and shikimate pathways. As an example, in the production of 
actinorhodin, the supply of malonyl-CoA from acetyl-CoA was increased through the 
overexpression of acetyl-CoA carboxylase resulting in a 6-fold increase. 56 Similarly, the 
overexpression of the first enzyme in the shikimate pathway, DAHP, resulted in an 
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increase in the expression of Balhimycin, which required the aromatic amino acids 
produced through the shikimate pathway. 57 The terpenoid pathways are among the 
extensively studied tools in metabolic engineering. Terpenoid pathways use both 
precursors DMAPP and IPP as building blocks for longer terpene compounds. 58 In 
production of NPs in E. coli, these precursors are usually supplied by improving the 
efficiency of the native MEP pathway or via the heterologous expression of a mevalonate 
pathway derived from higher organisms. 59-61 
 Empirical methods have also been used in the optimization of fermentation 
conditions for production of NPs. One example is in the optimization of 6-
deoxyerythronolide B production in E. coli, where the effect of media, and subsequently 
its individual components were studied. In this example, tryptone, and subsequently, 
tryptone components, glutamine, and threonine amino acids were found to increase 
compound production by a further 16-fold. 55 
The cyanobactin pathway is one of the few marine NP pathways that have been 
successfully expressed in a heterologous host. 5,20,28 Since the first expression of 
cyanobactins in E. coli, there have been continuous efforts to improve and optimize the 
expression system in order to establish a robust platform that can supply practical 
amounts of cyanobactins. 28,62However, despite the stability in the detection of 
compounds from the extracts, the best yield that we were able to obtain previously was 
300 µg/L. 
To improve the production of cyanobactins in E. coli, we used a combination of 
simple media and fermentation optimization, as well as co-expression of a heterologous 
mevalonate pathway to supply isoprene precursors. In Chapter 3, we show an overall 
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improvement in yield of about 100-fold, which is the highest titer for the expression of 
cyanobactins so far. With this ability to supply cyanobactins, we started to explore their 
bioactivities, which resulted in the discovery of a new activity for patellin 2 63 in dorsal 
root ganglia neurons.  
 
Engineering for expansion of cyanobactin diversity 
One key advantage that synthetic compound possess over natural products is that 
it is vastly easier to generate derivatives of synthetic compound in order to optimize the 
bioactivity of a given compound.  In contrast, it is much more difficult to discover or 
engineer natural product derivatives, and natural product chemists generally lack the 
ability to make deterministic changes in compounds, but are limited to what few 
derivatives are naturally occurring, or those that can be generated by disabling late-stage 
biosynthetic enzymes.   
Within this context, the cyanobactin pathway is particularly notable, in that it 
can be readily engineered to allow the production of derivative compounds due to the 
high substrate tolerance of the modifying enzymes. In the first proof of this capacity, the 
precursor peptide of the patellamide pathway, patE2, encoding the natural product 
ulithiacyclamide was modified to encode a peptide mimic of the rattlesnake venom 
peptide, eptifibatide. 22 The artificial cyanobactin was referred to as eptidemnamide, with 
the replacement of the original disulfide with an amide bond. Successful production of 
eptidemnamide demonstrated that cyanobactin enzymes are substrate-tolerant beyond just 
the natural cyanobactin sequences. Eptidemnamide contained charged amino acid 
residues, arginine, and aspartic acid, and others that were not found in natural 
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cyanobactins, specifically, glycine, tryptophan, and glutamine. 22 Successive experiments 
in the engineering of cyanobactins further supported this finding, including swapping of 
precursor peptides in the trunkamide pathway, 23 and producing a new cyanobactin called 
minimide in the tru pathway that was discovered by genome mining. 28 
The capacity of the cyanobactin pathway for generating chemical diversity was 
subjected to a quantitative test with the construction of random mutant libraries based on 
the sequence of trunkamide. Double and quadruple mutant subsets of a projected library 
of 3.2 million derivatives were expressed and chemically analyzed to examine the amino 
acid selectivity in the different positions of the compound. From these subsets, 58% of 
the unique mutant genes were produced in vivo. Libraries of 108 compounds were made, 
and by extrapolation from these experiments, a minimum of 106 compounds can be 
produced from a single cyanobactin pathway. 62   
 Although these experiments demonstrated that the cyanobactin pathway has a 
high substrate tolerance for proteinogenic amino acids, this does impose a limitation on 
the chemical diversity on cyanobactins.  Thus, we posed the question of whether it might 
be possible to incorporate functionalities beyond the 20 proteinogenic amino acids. 
Incorporation of non-proteinogenic amino acids are often hallmarks of non-ribosomal 
peptides, among which are some of the most bioactive natural products known. 64  NRPS 
pathways are widespread, but are extraordinarily difficult to engineer. 65,66Combining 
multistep, substrate-tolerant, RiPP pathways with the structural complexity of NRPS 
therefore would be an unprecedented and important advance in the development of 
natural products as drugs. In Chapter 4, we describe the successful incorporation of 
unnatural amino acids (UAAs) into cyanobactins. Prior to this report, the incorporation of 
! "#!
UAAs has only been done in proteins, 67 as well as in lantipeptides in vitro. 68  
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Bioactivity profile of ascidian chemical extracts
We assayed the chemical extracts of the ascidians
against laboratory strains of microorganisms to test
whether there are distinct differences in the potency
and toxicity of metabolites from the tropical regions
compared with the temperate regions. We tested for
activities against different microbes, including
Staphylococcus aureus, Escherichia coli and Myco-
bacterium tuberculosis. We also tested for cytotoxi-
city against a human CEM-TART cell line and for
antifungal activity against Candida albicans. There is
a clear geographical distribution of biological activity
and potency in these samples, which reflects the
results of the secondary metabolite analysis per-
formed as described below (Supplementary Figure
S8). In these assays, the most potent extracts were
those of tropical ascidians while the least potent are
those of temperate ascidians. Importantly, the toxicity
of these samples was not correlated to diversity of the
underlying microbiome but was independent of this
variable. This indicates that strains with more diverse
microbiomes do not produce more toxic compounds
and serves to further reinforce the role of single,
talented bacterial symbionts in the production of
toxins (see Discussion).
Chemistry of ascidians
PCA and hierarchical clustering of the LC/MS
profiles showed that ascidians generally grouped by
geographical location rather than by species
(Figure 5). Three major clusters are formed compris-
ing California, Florida and a combination of Papua
New Guinea and Vanuatu in a single cluster. We
hypothesized that this pattern was due to lipids in
the extracts, which likely vary, because different
temperatures would require different components to
maintain membrane fluidity (Parrish, 2013). Alterna-
tively, it might be due to other effects, such as
available food sources, although this seemed less
likely due to the large geographical sampling range in
the tropical Pacific. Using the PCA biplot of ascidians
and compounds (Supplementary Figure S5A), we
performed an initial identification of the extract
components that led to the geographical clustering
of the ascidians. The chromatographic peaks were
assigned using Lipid Maps (Fahy et al., 2007), and
the resulting peaks assigned to lipids were then
applied to PCA analysis. By using this putative lipid
subset, we observed the same clustering by geogra-
phical location in the PCA (Supplementary Figure
S5B). Conversely, we also subtracted the Lipid Maps-
assigned peaks from the whole mzxml files and
subjected the remaining data to PCA. Upon removing
putative lipids from the analysis, the clustering
according to geographical location was no longer
observed. Instead, clustering was better correlated
with animals species (see below).
A weakness of all MS-based approaches is that it is
difficult to be sure that an ion has been accurately
assigned. We therefore used further methods to
determine whether ions preliminarily assigned as
lipids did indeed truly represent lipids. We selected
representative extracts from each PCA cluster and
analyzed them using a validated metabolomics
method, in which fragmentation of lipids (MS/MS
profile) was compared with a large database of lipid
fragment patterns. Through this analysis, we con-
firmed that the major components responsible for
variance in the PCA were lipids. These included
phospho-glycerolipids, glycerolipids and some straight
chain fatty acids (Figure 5, Supplementary Figure S6).
We further analyzed the ascidian chemistry
between samples within the same geographical
location. We focused on Papua New Guinea samples
where we have groups containing replicates of the
same species and have characterized the natural
products chemistry (Donia et al., 2011b). By PCA, we
found that the samples cluster by host species. For
example, L. patella samples (one from Fiji and two
from Papua New Guinea) formed a separate cluster
that was strongly driven by secondary metabolites.
These metabolites include members of the cyanobac-
tin family: patellins 1, 2, and 5 (Carroll et al., 1996);
and the patellazoles (Corley et al., 1988; Zabriskie
et al., 1988) (Figure 6, Supplementary Figure S7).
Similarly, L. badium samples grouped together and in
correlation with varamines (Molinski and Ireland,
1989) and some other unknown metabolites. When
we included the Cystodytes sp. samples from
Vanuatu in this analysis, these also strongly clustered
together as expected, except for a single sample that
was phylogenetically different than the others
(Supplementary Figure S1). The grouping of Cysto-
dytes samples was also caused by secondary meta-
bolites, mostly pyridoacridine alkaloids (Marshall
and Barrows, 2004), and the variations within the
species were due to the abundance of different
compound analogs. Specifically, VN_08002 and
VN_08041 samples contained major amounts of
cystodytins while VN_08019 mainly contained sher-
milamines in the extract (Cooray et al., 1988;
Kobayashi et al., 1991).
In cases where they could be identified, secondary
metabolites were also noticeably major components of
extracts of other ascidians from Florida, such as the
eudistomins (Kobayashi et al., 1984) from Eudistoma
sp. TB1. The extract of L. bistratum also contained
major metabolites, including the bistramides and the
bistratamides group of compounds (Degnan et al.,
1989; Biard et al., 1994; Perez and Faulkner, 2003).
However, in most samples, especially those from
California, the majority of the components could not
be assigned from databases, such as Antimarin and
the Dictionary of Natural Products.
Discussion
We set out to determine whether there are any
correlations between ascidian bacterial commu-
nities and the presence of abundant, bioactive
Ascidian microbiomes and metabolomes
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!"#$%&'()*'+,-!"Ascidian tissue (~0.5 cm3) was ground in liquid nitrogen in sterile mortar and 
pestle. The powder obtained was resuspended in TE (5 mL) with lysozyme (2 mg ml-1) and 
incubated at 30 ºC for 1 hour. EDTA (0.5 M, 1.2 mL) was added to the solution and gently mixed, 
after which proteinase K (0.2 mg mL-1, Qiagen) was added and the solution was incubated at 30 ºC 
for 5 minutes. For cell lysis, SDS (10%, 0.65 mL) was added and the solution was incubated at 37 ºC 
for 3-4 hours. After visibly complete lysis (clear solution), NaCl (5M, 1.2 mL) was added, mixed, 
and CTAB/NaCl (1 mL) solution was added before incubation at 65 ºC for 1 hour. Standard 
phenol/chloroform extraction was then performed (Sambrook and Russell 2006). ""
!"#$%&'()+("
Processing and analysis of ascidian chemical extracts. Each ascidian was extracted for 1 hour with 
methanol (5 mL), and the methanol was removed and dried under vacuum. Each extract was 
dissolved in methanol:water (1:9; 1.1 mL) and loaded into a Gilson GX-271 liquid handling system. 
Samples (0.9 mL) were subjected to automated SPE (ThermoFisher Scientific HyperSep C18, 50 mg 
absorbent mass, 1 mL reservoir volume), washed with H2O (1 mL), and eluted with 95% methanol 
(1 mL) directly into an LC/MS-certified vial. Following SPE, each extract was quantified using an 
evaporative light-scattering detector (ELSD) according to previously published methods.(Adnani et 
al 2012) Each extract was diluted with 95% methanol to a concentration of 30 ng/mL.  
 
Methods S3 
Representative samples from different locations were analyzed for putative lipid components on an 
Agilent MS 6520 Q-TOF mass spectrometer fitted to an Agilent 1290 UPLC. The extract 
components were separated on Acquity UPLC CSH C18 column (1.7 !M, 2.1 X100 mm) using the 
! "#!
following gradient at 0.3 mL min-1 (mobile phase A:B): t = 0, 85:15; t = 0-4 min, gradient to 70:30; t 
= 4-5, gradient to 48:52; t = 5-22, gradient to 18:82; t = 22-23, gradient to 1:99; t = 23-30, 1:99.  
Mobile phase A consisted of acetonitrile:water (60:40 v/v) in 10 mM ammonium formate and 0.1% 
formic acid, and mobile phase B consisted of isopropyl alcohol:water (90:10 v/v) in 10 mM 
ammonium formate and 0.1% formic acid. The column temperature was set to 65 oC. Acquisition 
was performed in positive ESI mode acquiring from m/z 100-1700. The mass spectrometer was 
operated using the following parameters: dry gas temperature, 350 oC; dry gas flow, 11.1 L/min; 
nebulizer pressure, 24 psig; Vcap, 5000V; fragmentor, 250 V.  Additional parameters (precursors per 
cycle, 2; absolute threshold, 200) were used for data-dependent MS/MS. 
 
Methods S4 
Antimicrobial broth dilution assays. The assay was performed as previously described(Koch et al 
2010) with the exception that four wells per compound were used for each dilution for MIC 
determination. DMSO served as a negative control. Bacterial strains used, along with the positive 
control antibiotic for each strain, were M. tuberculosis H37Ra ATCC 25177 (rifampicin); E. coli 
ATCC 25922 (gentamicin); B. subtilis ATCC 6633 (gentamicin); and S. aureus ATCC 25923 
(gentamicin) and C. albicans ATTC 90028 (itraconazole). 
 
Cytotoxicity assay. Cytotoxicity testing was performed using CEM-TART lymphoblastoid 
cells(Chen et al 1992) cultured in RPMI-1640 with 20% fetal bovine serum and 
antibiotic/antimycotic supplement at 37 °C with 5% CO2 in moisture saturated atmosphere in 96-
well culture clusters as previously described (Lin et al 2013).  !!!!
! "#!
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CA_Ascidia_sp_4-19 20-Feb-11 Catalina Island, 33
o 26.95 ' N, 
118o 29.94' W Ascidia ceratodes, L12378.2 99 F1/R1 
CA_Botryllus_sp_5-19 12-Oct-11 Catalina Harbor Bottrylus planus, DQ346653.1 99 F3/R3 
CA_Didemnum_sp_4-
17 20-Feb-11 
Catalina Island, 33o 26.95' N, 





CA_Didemnum_sp_4-2 19-Feb-11 Catalina Island, 33
o 26.92' N, 
118o 28.64' W 
Didemnum molle, 
AB211071.1 92 F3/R3 
CA_Didemnum_sp_4-7 19-Feb-11 Catalina Island, 33
o 26.92' N, 
118o 28.64' W 




CA_Didemnum_sp_5-1 10-Oct-11 Catalina Island, 33
o 26.69' N, 
118o 28.92' W 






Catalina Island, 33o 26.87' N, 







Catalina Island, 33o 26.21' N, 





CA_Pyura_sp_4-21 19-Feb-11 Catalina Island, 33
o 26.67' N, 
118o 29.417' W Pyura haustor, AY903926.1 99 F3/R3 
CA_Styela_sp_5-16 11-Oct-11 Catalina Harbor Styela plicata, L12444.2 99 F3/R3 
FJ_Lissoclinum_patella
_06037  Fiji, 17
o55' S, 177o16' E Lissoclinum patella, AB211085.1 99 F1/R1 
FL_Didemnum_sp_TB3
*(D.psammathode) 15-Aug-11 
Florida Keys, 24 o 41.672' N, 
81o 26,797' W 
Didemnum sp. Whangamata-





Florida Keys, 24 o 39.591' N, 
81 o 25.217' W 
Ecteinascidia turbinata, 
FM244848.1 99 F3/R3 
FL_Ecteinascidia_turbi
nata_TB2 15-Aug-11 
Florida Keys, 24 o 39.453' N, 
81 o 25.247' W 
Ecteinascidia turbinata, 
FM244848.1 99 F3/R3 
FL_Eudistoma_sp. _004 
*(E. hepaticum) 28-Oct-10 
Florida Keys, 24 o 41.078 N, 






*(E. olivaceum) 1-Sep-11 
Florida Keys, 24 o 41.685' N, 






01BB *(T. orbicatum) 11-Oct-10 
Florida Keys, 24 o 37.487' N, 
81 o 27.443' W 
Trididemnum paracyclops, 
AB211077.1 92 F1/R1 
FL_Trididemnum_sp_T
B4 *(T. palmae) 15-Aug-11 
Florida Keys, 24 o 37.487' N, 







Papua New Guinea, 10° 16' S, 







Papua New Guinea, 10° 2' S, 
145° 33' E 






Papua New Guinea, 9° 36' S, 







Papua New Guinea, 10° 16' S, 
145° 38' E 
Lissoclinum patella, 
AB211085.1 99 F1/R1 
PNG_Lissoclinum_pate
lla_11040 9-Nov-11 
Papua New Guinea, 10° 16' S, 
145° 38' E 
Lissoclinum patella, 
AB211085.1 99 F1/R1 
PNG_Lissoclinum_vare
au_11047 10-Nov-11 
Papua New Guinea, 10° 8' S, 
145° 35' E 
Lissoclinum badium, 
AB211078.1 86 F3/R3 
PNG_Lissoclinum_vare
au_11062 11-Nov-11 
Papua New Guinea, 10° 2' S, 
145° 32' E 
Lissoclinum badium, 
AB211078.1 86 F3/R3 
PNG_Lissoclinum_vare
au_11068 11-Nov-11 
Papua New Guinea, 10° 2' S, 
145° 32' E 
Lissoclinum badium, 




Papua New Guinea, 9° 35' S, 
147° 17' E 
Lissoclinum badium, 
AB211078.1 87 F3/R3 
PNG_Lissoclinum_bistr
atum *(L. voeltzkowi) 05-Oct-07 
Papua New Guinea, 4° 8' S, 
151° 34' E 
Lissoclinum bistratum, 
AB211084.1 99 F1/R1 
VN_Cystodytes_sp_080
02 28-Oct-08 
Vanuatu, 15° 32.496' S, 





Vanuatu, 15° 36.675' S, 167° 





Vanuatu, 15° 25.416' S, 167° 




Number of tunicate samples 32 
Number of filtered reads 217073 
Number of 97 % OTUs 3982 
Counts statistics (min/max/average) 572/31660/6784 
OTUs statistics (min/max/average) 10/804/207 !!!
!"#$%&')*&.$+,!'/!0&$)*&+!1+*2!$3!,4$+!+,125&!
Primer Sequence (5’-3’) Source 
AscF1  CTGGTTGATCCTGCCAG Yokobori, 2006 (Yokobori et al 2006) 
AscR1  CACCTACGGRWACCTTG Yokobori, 2006 (Yokobori et al 2006) 
AscF3 GATCCTGCCAGTAGTBATAT Yokobori, 2006 (Yokobori et al 2006) 








18S1  CCTGGTTGATCCTGCCAG Tsagkogeorga, 2009 (Tsagkogeorga 2009) 
18S2  TAATGATCCATCTGCAGG Tsagkogeorga, 2009 (Tsagkogeorga 2009) 
27F AGAGTTTGATCMTGGCTCAG Lane, 1991 (Lane 1991) 
1492R CGGTTACCTTGTTACGACTT Turner, 1999 (Turner et al 1999) 
939F TTGACGGGGGCCCGCACAAG RTL in house primer !!!
! "#!!!!
!"#$%&'()&"#$%#&'#!'(%&)*!+&,!+-./+!,01#2*0)3!1+-%#*!(4!+*'0,0+&!50'2(60(5#*!5#+*%2#,!%*0&7!,044#2#&)!,01#2*0)3!0&,0'#*8!!
Sample Counts  OTU Shannon Simpson Chao1 
CA_Ascidia_sp_4-19 2213 248 6.19 0.96 255.40 
CA_Botryllus_sp_5-19 2406 220 5.68 0.94 229.67 
CA_Didemnum_sp_4-17 3992 136 3.27 0.77 156.53 
CA_Didemnum_sp_4-2 2959 106 2.87 0.68 117.12 
CA_Didemnum_sp_4-7 2681 160 4.09 0.82 168.22 
CA_Didemnum_sp_5-1 2478 170 4.86 0.92 182.00 
CA_Didemnum_sp_5-11 3312 140 3.59 0.83 167.04 
CA_Didemnum_sp_5-18 5068 149 3.15 0.67 152.89 
CA_Pyura_sp_4-21 2841 58 2.54 0.73 60.50 
CA_Styela_sp_5-16 2037 163 4.97 0.92 169.88 
FJ_Lissoclinum_patella_06037 1594 209 4.35 0.84 393.53 
FL_Didemnum_sp._tb3 7454 429 5.62 0.92 446.73 
FL_Ecteinascidia_turbinata_5 10015 234 3.60 0.80 268.55 
FL_Ecteinascidia_turbinata_tb2 31660 804 4.56 0.85 836.25 
FL_Eudistoma_sp_004 13886 41 0.78 0.17 50.00 
FL_Eudistoma_sp_tb1 12822 667 5.27 0.86 699.72 
FL_Trididemnum_sp_001BB 1007 74 3.72 0.84 78.57 
FL_Trididemnum_sp_tb4 572 10 0.61 0.15 10.25 
PNG_Didemnum_sp_11038 14155 166 5.09 0.93 178.55 
PNG_Didemnum_sp_11055 3372 290 6.79 0.98 300.44 
PNG_Didemnum_sp_11089 5585 236 5.38 0.95 241.70 
PNG_Lissoclinum_badium_11062 3916 92 4.20 0.90 98.18 
PNG_Lissoclinum_badium_11068 8993 104 3.24 0.80 108.62 
PNG_Lissoclinum_badium_11083 20324 278 2.40 0.56 284.36 
PNG_Lissoclinum_badium_11047 1899 44 3.25 0.81 48.50 
PNG_Lissoclinum_patella_11033 12851 347 3.08 0.65 368.72 
PNG_Lissoclinum_patella_11040 13778 186 2.55 0.64 195.60 
PNG_Lissoclinum_sp_7062 5528 114 4.39 0.88 121.00 
PNG_Lissoclinum_bistratum 11015 475 3.68 0.64 779.59 
VN_Cystodytes_sp_08002 2578 106 4.51 0.90 109.00 
VN_Cystodytes_sp_08019 1610 97 4.49 0.92 100.62 
VN_Cystodytes_sp_08041 2472 110 4.19 0.89 114.50 
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!"#8&(,)5#-.#/019 !.0&%" !.0&%" !.0&%" !.0&%"
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7,*)3)=>?@ A08<,4/0%B;4)<,)608<,4/0%BC0990:4)<,)608<,4/0%B(D4)90</0.,+%B%B%B >E@F5 ?>
7,*)3)@@F A08<,4/0%B;4)<,)608<,4/0%BC0990:4)<,)608<,4/0%B2.<,4)9)*070.,+%B2.<,4)9)*0708,0,%BC.08/,8).0%B >E@>5 F>
7,*)3)=GHI A08<,4/0%BA08<,4)/7,<,+%BJ.03)608<,4//0%BJ.03)608<,4/0.,+%BJ.03)608<,4/08,0, >E@K5 F>
7,*)3)==LH A08<,4/0%B(M0*)608<,4/0%B(D.)4):.0+<%BN<409,*):/.,+%B%B%B >E>H5 F>
7,*)3)G? A08<,4/0%BA08<,4)/7,<,+%BJ.03)608<,4//0%BJ.03)608<,4/0.,+%BJ.03)608<,4/08,0,%B%B >E>F5 K>
7,*)3)@HLG A08<,4/0%B;4)<,)608<,4/0%B2.:D0:4)<,)608<,4/0%BOD/P)6/0.,+ >E>K5 K>
7,*)3)GGK@ A08<,4/0%B28/7)608<,4/0%BN30>?GK%BN30>?GK%B%B%B >EG@5 K>
7,*)3)GHLI A08<,4/0%B;4)<,)608<,4/0 >E>F5 K>







7,*)3)>?@ A08=,4/0%B<4)=,)608=,4/0%BC0990:4)=,)608=,4/0 ?D@>5 E>
7,*)3)>EE A08=,4/0%B<4)=,)608=,4/0%BC0990:4)=,)608=,4/0%BF/64/)*0;,+%BF/64/)*08,0,%BF/64/) ?D@@5 E>
7,*)3)@@?@ A08=,4/0%B<4)=,)608=,4/0%BC0990:4)=,)608=,4/0 ?D?G5 E>
7,*)3)@HHI A08=,4/0%B<4)=,)608=,4/0%B',;=0:4)=,)608=,4/0%B',+-;J)608=,40;,+%B',+-;J)6-;608,0,%B% ?D?G5 E>
7,*)3)@KGL A08=,4/0%B<4)=,)608=,4/0%BC0990:4)=,)608=,4/0 >DH@5 E>
7,*)3)@GHM A08=,4/0 ?DHG5 E>
7,*)3)@LH@ A08=,4/0%B<4)=,)608=,4/0%BC0990:4)=,)608=,4/0%B"8,0*)+:/4/;;0;,+%B./=)4/8);08,0,%B./=)4/8);0% ?DHG5 E>
7,*)3)IIL? A08=,4/0%B<4)=,)608=,4/0%BC0990:4)=,)608=,4/0%BN0*=O)9)*070;,+%B%B% ?D?I5 E>































7,*)3)>?@A B08=,4/0%C(D0*)608=,4/0%C"+8/;;0=)4/):ED8/7,0,%C(E4))8)880;,+%C<4)8E;)408,0,%C<4)8E;)4)*%C F@GHI5 >HH
7,*)3)J?@K B08=,4/0%C<4)=,)608=,4/0%C2;:E0:4)=,)608=,4/0 @GI@5 >HH
7,*)3)JFHF B08=,4/0%C<4)=,)608=,4/0%CL0990:4)=,)608=,4/0 @G>A5 >HH
7,*)3)>M?A B08=,4/0%C(D0*)608=,4/0%C"+8/;;0=)4/):ED8/7,0,%C(E4))8)880;,+%C<4)8E;)408,0,%C<4)8E;)4)*%C >HGA@5 >HH
7,*)3)IIM B08=,4/0%C<4)=,)608=,4/0%C2;:E0:4)=,)608=,4/0 HG>F5 >HH
7,*)3)IMJ B08=,4/0%C<4)=,)608=,4/0%C2;:E0:4)=,)608=,4/0%CNE)7)+:/4/;;0;,+ JGAA5 >HH
7,*)3)>KAA B08=,4/0%C(D0*)608=,4/0%C(E;)4):;0+=%CO=409,*):/;,+%C%C%C HG>J5 >HH
7,*)3)JM> B08=,4/0%C(D0*)608=,4/0%C"+8/;;0=)4/):ED8/7,0,%C(E4))8)880;,+%C<4)8E;)408,0,%C<4)8E;)4)*%C HG>H5 >HH




































7,*)3)=>?@ A08<,4/0%B;4)<,)608<,4/0%B',.<0:4)<,)608<,4/0%BC30DEF=%B%B%B =>GHI5 IF
7,*)3)=>HI A08<,4/0%B;4)<,)608<,4/0%B2.:J0:4)<,)608<,4/0 ?GDE5 IF
7,*)3)KFHI A08<,4/0%B(L0*)608<,4/0%B"+8/..0<)4/):JL8/7,0,%B(J4))8)880.,+%B;4)8J.)408,0,%B;4)8J.)4)*%B @GF@5 IF
7,*)3)@HI@ A08<,4/0%B;4)<,)608<,4/0%B',.<0:4)<,)608<,4/0%B',+-.M)608<,40.,+%BN/<4)+:/*08,0,%BN/<4)+:/*0%B >G>>5 IF
7,*)3)@I> A08<,4/0%B;4)<,)608<,4/0 KGEK5 IF
7,*)3)K?II A08<,4/0%B;4)<,)608<,4/0%B2.:J0:4)<,)608<,4/0%BOJ/P)6/0.,+%B;JL..)608<,4/08,0,%BQ,+)4J/P)6/-9%B @G>E5 IF
7,*)3)K?=H A08<,4/0%B;4)<,)608<,4/0%BR0990:4)<,)608<,4/0 DGIE5 IF
7,*)3)=@E> A08<,4/0 DGI@5 IF







7,*)3)=>?@ A08<,4/0%B;4)<,)608<,4/0%B2.:C0:4)<,)608<,4/0 D?E>=5 DFF
7,*)3)=F?D A08<,4/0%B;4)<,)608<,4/0%BG0990:4)<,)608<,4/0%B;+,-7)9)*070.,+%B;+,-7)9)*0708,0,%B;+,-7)9)*0+ >E=F5 DFF
7,*)3)D@HI A08<,4/0%B;4)<,)608<,4/0%B',.<0:4)<,)608<,4/0%BA7,..)3/64/)*0.,+%BA7,..)3/64/)*08,0,%BA7,..)3/64/)%B DEDD5 DFF
7,*)3)>= A08<,4/0%B;4)<,)608<,4/0%BG0990:4)<,)608<,4/0%B;+,-7)9)*070.,+%B;+,-7)9)*0708,0, FEDI5 DFF
7,*)3)=HI> A08<,4/0%B;4)<,)608<,4/0 FEDJ5 DFF
7,*)3)DHI= A08<,4/0%B;4)<,)608<,4/0%B2.:C0:4)<,)608<,4/0%BKC/L)6/0.,+ FEFH5 DFF
7,*)3)J=F@ A08<,4/0%B;4)<,)608<,4/0%BG0990:4)<,)608<,4/0%B"8,0*)+:/4/..0.,+%BM*7)L)/8/9)*08,0,%B%B FEDN5 ?N
7,*)3)HIF A08<,4/0%B;4)<,)608<,4/0%BG0990:4)<,)608<,4/0 FEF>5 ?N




Ascidian sample Symbiotic eukaryote 
Genbank accession 
number 
Eudistoma sp. 004 Aiptasia mutabilis FJ489438.1 
  Prostheceraeus vittatus AJ312272.1 
  Aiptasia pulchella AY297437.1 
Didemnum sp. 4-7 Grateloupia luxurians U33132.1 
Didemnum sp. 4-17 Clytia gracilis DQ068053.1 
  Clytia sp. AGC-200 AF358074.1 
Didemnum sp. 5-1 Baeria nivea AF182191.1 
Didemnum sp. 5-11 Selaginopsis cornigera Z92899.1 
  Uncultured eukaryote clone SS1_E_02_11 EU050966.1 
Didemnum sp. 5-18 Igernella notabilis EU702420.1 
  Rhacostoma atlantica EU305501.1 
  Melicertum octocostatum AY920757.1 
Cystodytes sp. 08002 Lankesteria ascidiae JX187607.1 
  Uncultured eukaryote clone SS1_E_02_1 EU050966.1 
Cystodytes sp. 08019 Corallochytrium limacisporum L42528.1 
  Notodelphys prasina JF781536.1 
  Cyclopina gracilis  JF781537.1 
Cystodytes sp. 08041 Symbiodinium sp.  AY165766.1 
  Notodelphys prasina  JF781536.1 
  Lankesteria ascidiae JX187607.1 
Didemnum sp. 11038 Uncultured eukaryote clone CC02A105.033  KF031747.1 
  Cyclopina gracilis JF781537.1 
  Doridicola agilis JF781541.1 
Didemnum sp. 11055 Cyclopina gracilis F781537.1 
  Anticomidae sp. JCC29 HM564572.1 
Didemnum sp.11089 Melicertum octocostatum AY920757.1 
  Dictyota sp. YMGTB002 AB087109.1 
  Uncultured alveolate  FN263032.1 
Eudistoma sp. TB1 Calomicrolaimus parahonestus AY854218.1 
  Sycettusa aff. hastifera OV-2012  JQ272322.1 
  Spongia tubulifera KC902150.1 
  Grantessa sp. OV-2012 voucher GW979 JQ272312.1 
Didemnum sp. TB3 Posidonia australis GQ497582.1 
  Spyridia filamentosa  EU718707.1 
  Attheyella crassa EU380307.1 
Trididemnum sp. TB4 Biemna fistulosa FR819688.1 
  Thelepus crispus JN936473.1 




Sample Code Host 
Taxonomy 





Previous microbiome analysis 
of related species 
CA_Ascidia_sp_4-19 Ascidia 
ceratodes 
California    
CA_Botryllus_sp_5-19 Bottrylus 
planus 
California    
CA_Didemnum_sp_4-17 Didemnum sp. California    
CA_Didemnum_sp_4-2 Didemnum sp. California    
CA_Didemnum_sp_4-7 Didemnum sp. California    
CA_Didemnum_sp_5-1 Didemnum sp. California    
CA_Didemnum_sp_5-11 Didemnum sp. California    
CA_Didemnum_sp_5-18 Didemnum 
molle 
California    
CA_Pyura_sp_4-21 Pyura haustor California    
CA_Styela_sp_5-16 Styela plicata California plicatamide  Erwin et al, 2013 
FL_Didemnum_sp_tb3 Didemnum sp. Florida    
FL_Ecteinascidia_turbinata_5 Ecteinascidia 
turbinata 
Florida ecteinascidins Ca. 
Endolisoclinum 
frumentensis 






Florida ecteinascidins Ca. 
Endolisoclinum 
frumentensis 
Rath 2011, Perez 2007, Moss 
2003 
FL_Eudistoma_sp_004 Eudistoma sp. Florida eudistomins   
FL_Eudistoma_sp_tb1 Eudistoma sp. Florida eudistomins   
FL_Trididemnum_sp_001BB Trididemnum 
sp. 
Florida    
FL_Trididemnum_sp_tb4 Trididemnum 
sp. 
Florida    
PNG_Didemnum_sp_11038 Didemnum sp. Papua New 
Guinea 
   
PNG_Didemnum_sp_11055 Didemnum sp. Papua New 
Guinea 
   
PNG_Didemnum_sp_11089 Didemnum sp. Papua New 
Guinea 













Schmidt 2005, Donia 2008, 









Prochloron spp., Schmidt 2005, Donia 2008, 











Schmidt 2005, Donia 2008, 
Kwan 2012, Behrendt 2012 
PNG_Lissoclinum_sp_7062 Lissoclinum sp. Papua New 
Guinea 









Nitrospina sp. Erwin 2013 
PNG_Lissoclinum_badium_1 Lissoclinum Papua New pyridoacridine Nitrospina sp. Erwin 2013 
! "#!

























Prochloron spp.,  
VN_Cystodytes_sp_08002 Cystodytes sp. Vanuatu pyridoacridine 
alkaloids 
  
VN_Cystodytes_sp_08019 Cystodytes sp. Vanuatu pyridoacridine 
alkaloids 
  
VN_Cystodytes_sp_08041 Cystodytes sp. Vanuatu pyridoacridine 
alkaloids 
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Figure S1. The phylogenetic tree of ascidians using 18S rRNA gene sequences. Sequences 
obtained from this study are labeled with location (CA, FL, PNG, VN) and sample code. Other 
sequences were obtained from NCBI with the following accession numbers: Megalocercus 
huxleyi FM244868.1, Herdmania litoralis AB564300.1, Pyura haustor AY903926.1, Pyura  
spinifera JF961826.1, Ecteinascidia turbinata FM244848.1, Phallusia fumigata FM244844.1, 
Ascidia ceratodes L12378.2, Aplidium pliciferum AB211067.1, Eudistoma gilboviride 
AB211069.1, Cystodytes sp_TG-2008 FM244842.1, Lissoclinum badium AB211078.1, 
Lissoclinum bistratum AB211084.1, Lissoclinum patella AB211085.1, Didemnum sp DidSB 
AB211073.1, Trididemnum paracyclops AB211077.1, Didemnum molle AB211071.1, Didemnum 
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Figure S2. Abundance and order level composition of Deltaproteobacteria (A) and 
Gammaproteobacteria (B) showing ascidian species specificity of the most abundant groups. (C) 
Phylogeny of the top ten most abundant OTUs in L. patella and E. turbinata samples, arrows 
indicate known natural products producers. Bar plots and phylogenetic trees were generated using 


















































































































































































































































































































































































































Figure S3. Effects of seasonal variation on the composition of ascidian microbiomes. The graph 
shows that the major phyla (filtered to top 20 percent) are maintained in ascidians collected from 




















































































Figure S4. UniFrac-based 3D PCoA plots of all samples showing the clustering of samples 
according to (A) type of organisms (black: ascidians, red: mollusks) and (B) location (black: CA, 





Figure S5. PCA biplots of (A) ascidian organic extracts showing correlation of samples from the 
same location (red arrows) with specific extract components (black print indicating retention time 
and m/z (B) resulting PCA biplot of assigned lipids after assignment of the LCMS data through 















































Figure S6. Example LC-MS/MS spectra of lipids that were correlated with extracts from 
different locations (PCA biplots are shown on the left panels). Compounds or compound families 
were identified by comparison of MS/MS fragmentation patterns and accurate masses to 




































Figure S7A. PCA of samples from Papua New Guinea showing a clustering  




























































































































































































































Figure S8. Bioactivity profile of ascidian extracts showing the distribution of bioactivity across 
different locations. Activities are shown as percent growth inhibition relative to standard 
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 The limited supply of natural products remains the single most important 
bottleneck in natural products drug discovery and development. Heterologous expression 
of biosynthetic pathways is often perceived as a ready solution to supply natural products 
from uncultivable microbes, but obtaining useful quantities of metabolites from 
heterologous expressions is far from straightforward, especially for complex, multistep 
pathways.  Cyanobactins are among the few metabolites from ‘unculturable’ bacteria that 
have been successfully expressed in heterologous hosts. Cyanobactins belong to the 
growing class of ribosomally synthesized and posttranslationally modified peptides 
(RiPPs).  One notable feature of RiPPs is that in some cases, combinatorial libraries of 
active compounds can be generated via the straightforward mutagenesis of precursor 
peptides. Cyanobactins are exemplary in this respect, as a recent study demonstrated that 
>106 compounds could be produced in this fashion.  However, supply issues persist even 
in heterologous expression experiments, with typical titers ranging from 10-100 µg/L, 
with the highest reported yield 300 µg/L.  Here we present a greatly improved platform 
for the production of cyanobactins in E. coli, resulting in a 100-fold increase in titer. To 
showcase this method, we apply heterologously produced cyanobactins to a broad 
phenotypic assay on mice dorsal root ganglia (DRG) neurons, and discover a new activity 







 During the past decade, natural products discovery has shifted from purely 
chemical isolation approaches to a hybrid of chemical and bioinformatic methods.1-3  As 
a result, the number of biosynthetic pathways for both known and unknown compounds 
has vastly increased. However, the ability to rapidly discover novel compounds has 
thrown an old problem back into focus, namely that of how we can supply sufficient 
quantities of natural products for practical drug discovery and development. This problem 
is particularly severe for metabolites discovered in rare animals, or for those metabolites 
predicted from genome sequences. 4  We have provided an important and instructive 
example of how this problem can be addressed in our work on the discovery, 
characterization, and heterologous expression of cyanobactin pathways.5-11 Cyanobactins 
are a broadly-distributed group of small (usually 6-10 amino acid) posttranslationally 
modified peptides with diverse bioactivities including anticancer,12,13 antimalarial ,14  and 
antiviral 15 activities. 
 In RiPP biosynthesis, the amino acid sequence of the resulting natural product is 
encoded on a precursor peptide that, after ribosomal synthesis, is modified by enzymes to 
add chemical diversity, or to render peptide structures more drug-like. 16 The modifying 
enzymes generally exhibit relaxed substrate specificity, such that mutations in the 
precursor peptides are easily tolerated, leading to new compound derivatives.17,10,18 The 
biosynthetic steps in cyanobactin maturation have been characterized extensively. The 
promiscuity of the modifying enzymes in the cyanobactin pathways allows for the 
generation of libraries of derivatives, both natural6 19 and engineered. 6,10,20 Assessment of 
the capacity of a cyanobactin pathway to generate compound libraries in vivo projects 
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that a simultaneous five-site saturation mutagenesis library of one precursor sequence 
could produce 2 x 105 cyanobactin derivatives.20   
 The most studied cyanobactin pathways to date are derived from unculturable 
cyanobacterial symbionts of marine tunicates of the genus Prochloron.21,22 Given this 
obstacle to traditional fermentative approaches of natural product production and 
isolation, the alternative routes of chemical synthesis, heterologous expression, or in vitro 
synthesis are presently the only means of supplying cyanobactins. Considering that the 
medicinal appeal of cyanobactin pathways is tied to the possibility of creating 
cyanobactin libraries, heterologous expression is clearly preferable to chemical synthesis 
or in vitro reconstitution, as it allows the screening of huge libraries in easily 
transformable E. coli strains. 20  Accordingly, the cyanobactin pathways have been 
successfully manipulated in E. coli, and the potential of this heterologous system to 
produce novel derivatives has been demonstrated repeatedly. 23, 17,20  However, the yields 
are insufficient for practical purposes (drug screening, pharmacokinetics, animal testing 
etc.), as the best reported fermentation yield of cyanobactins is 300 µg/L.  
 In this work, we describe a greatly improved platform for the production of 
cyanobactins in E. coli. We achieve this through a combination of both exogenous and 
endogenous supply of additives and precursors. Specifically, we find that supplementing 
cultures with L-cysteine and co-expressing a previously reported heterologous 
mevalonate pathway24 to increase isoprene availability lead to significant increases in 
compound production; these approaches combine synergistically to net a 100-fold 
increase in cyanobactin titer. We further demonstrate that mevalonate pathway 
coexpression improves the yield of both prenylated and unprenylated cyanobactins.  We 
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showcase the usefulness of this expression system with the heterologous production and 
resulting discovery of the activity of the natural cyanobactin patellin 2 on dorsal root 
ganglia (DRG) neurons.  
 
Results 
Optimization of cyanobactin expression conditions 
 In the course of our optimization of the production of cyanobactins in E. coli, we 
have identified many different parameters that affect compound production. These 
include the volume of the liquid cultures, fermentation time, temperature, as well as 
different additives including amino acids, redox reagents, and metals. Previous 
publications have explored various strategies (i.e., different cell lines, promoters, media) 
to optimize cyanobactin expression. 23, 20  We compared expressions from 6 mL, 10 mL, 
100 mL, and 250 mL expressions. We also performed 1L fermentations in flasks and in a 
1 L fermentor. We determined that 6 mL cultures in 24-well plates gave us the maximum 
amount of compounds per volume of expression. We also compared the number days of 
expression from 2 to 7 days and determined that the maximum amount of compounds 
was obtained from 5 day expressions.  This experimental set-up also allowed us to study 
the expressions under many different conditions in replicate experiments reducing the 
preparation and extraction time as well as materials cost.  
 We next examined how cyanobactin yield was affected by growth media 
composition as well as additives including metals, redox agents, amino acids and 
different cofactors (Table 3.1). We first found that a mixture of methionine and cysteine 
increased compound production. Further analysis with the individual amino acids showed  
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that cysteine was responsible for the observed effect, and leads to a ~10-fold increase in 
compounds by LC/MS (Figure 3.1). We therefore added cysteine (5 mM) in all 
succeeding experiments. The mechanism of increase in compound production due to 
cysteine will be described elsewhere.  
 
Limited supply of isoprene precursors in E. coli 
 We previously observed that production of cyanobactins in E. coli yielded a 
mixture of cyanobactins with either zero, one, or two isoprene units added to Ser and Thr 
residues.10 20  This is also apparent in Figure 3.1. We hypothesized that this was due to 
the limited availability of the necessary isoprene precursor, DMAPP in E. coli, and that 
increasing the intracellular DMAPP concentration would increase our yield of the 
desired, doubly prenylated cyanobactins. To increase supply of DMAPP, we co-
expressed the second half of the mevalonate pathway (mev) from Saccharomyces 
cerevisiae that was previously engineered in E. coli for the production of amorphadiene, 
a precursor to the antimalarial drug artemisinin.24 When using only the latter half of the 
















Figure 3.1. Increase in cyanobactin production upon addition of cysteine (5mM). Labels 
indicate the cyanobactin derivatives (compound number). 
 
produce this metabolite.  Our new expression system therefore involved the coexpression 
of tru with the mevalonate pathway (mbi) pathway.  We supplemented these 
coexpressions with both mevalonate and cysteine (Figure 3.2). As anticipated, we 
observed an increased proportion of prenylated products in tru/mbi coexpressions (with 
added cysteine) when mevalonate was added (Figure 3.3). To further confirm that this 
was due to the addition of mevalonate, we fed 13C-labeled mevalonate to tru/mbi 
coexpressions. Mass analysis showed that the labeled 13C-labeled mevalonate was 
converted to DMAPP and was incorporated into the final compounds as evidenced by a 
+2 Da shift observable by LC-MS (Figure 3.4). This was also apparent in the masses of 
the fragment ions, showing the loss of one and two 13C labeled isoprene units (inset).  









































Figure 3.2. Expression system design using the combination of tru and mevalonate 
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Figure 3.3 Limited amount of isoprene precursors in E. coli. A) Increase in prenylation 
levels in the presence of mevalonate pathway in mbi plasmid and mevalonate (10 mM).  
B) Structure of cyanobactins produced in E. coli. 
 
tru pathway in vivo and can be used to increase the fraction of fully prenylated 
cyanobactins. 
 
Effect of mevalonate pathway coexpression on cyanobactin titer 
 Although mbi-coexpression had the desired effect of increasing the fraction of 
fully prenylated compounds, we were somewhat concerned that metabolic stress due to 
coexpression of the mevalonate pathway might decrease overall cyanobactin titer.  Thus, 















































Figure 3.4.  Incorporation of 13C-DMAPP into cyanobactin prenyl groups; inset shows 
loss of a labeled prenyl group from MS fragmentation. The peak at 943.5718 m/z shows 
the unlabeled patellin 3 and the 945.5777 m/z shows the incorporation of two 13C-
DMAPP in patellin 3. 
 
total amount of compounds.  In the presence of mevalonate (20 mM) and cysteine (5 
mM) (in tru/mbi coexpressions), the total amount of cyanobactins was increased 
consistently by about 100-fold compared to tru only expressions.  
 To test whether the increased titers were due to the products of the mevalonate 
pathway (i.e., increased DMAPP levels), and not from background effects due to 
coexpression with the mbi plasmid, we added increasing amounts of mevalonate into the 
tru/mbi expressions from 1 to 40 mM. A clear mevalonate-dependent increase in the total 
amount of cyanobactins was observed (Figure 3.5F-I). In expressions with 40 mM 
mevalonate, the total amount of compounds was estimated at 27 mg/L, nearly 100-fold 












Figure 3.5. Increased cyanobactin production in the presence of mevalonate pathway and 
mevalonate. Y-axis shows that amount of total compounds produced in each expression 
condition (columns) in mg/L. Column A) tru B) tru + 5mM cys, C) tru/mbi, D) tru/mbi + 
5mM cys, E) tru/mbi +10mM mevalonate, F) tru/mbi +5 mM cys + 5 mM mevalonate, 
G) tru/mbi + 5 mM cys + 10 mM mevalonate, H) tru/mbi + 5 mM cysteine + 20 mM 
mevalonate, I) tru/mbi + 5 mM cysteine + 40 mM mevalonate. Inset: comparison of tru 
and truDF1 knockout expression showing the relative amounts of unprenylated patellin 3  
 
the presence of both cysteine and mevalonate in tru/mbi expressions. Cysteine by itself 
consistently increased compound production, but to a much lesser extent (Figure 3.5B).  
Similarly, mevalonate pathway coexpression in the absence of cysteine gave only small 
increases in cyanobactin titer (Figure 3.5E).   
 The observation of an epistatic relationship between cys-supplementation and 
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of added cysteine) suggested to us that these two interventions might exert their effects 
on different stages of biosynthesis, with Cys-supplementation affecting earlier steps and 
mbi-coexpression affecting later steps of biosynthesis.  Such a proposal would be 
consistent with the accepted order of biosynthesis, in which prenyltransfer is believed to 
be the final step in biosynthesis. 9 
 Complicating this straightforward picture is the observation that all compounds, 
including unprenylated derivatives, are present at increased levels when the mevalonate 
pathway and  mevalonate were added, indicating that the increases in cyanobactin titer 
cannot be explained solely by the increased availability of isoprene donors such as 
DMAPP. To further probe the role of the mevalonate pathway, we knocked out the 
functional pathway prenyltransferase, truF1. Consistent with the above results, tru !F1, 
showed mevalonate-dependent increases in cyanobactin expression, giving rise to only 
the unprenylated compounds (Figure 3.5, inset). 
 Certain families of cyanobactins are not modified by isoprene. For example, in the 
patellamide pathway, pat, threonine and serine residues are heterocylized to yield the 
corresponding oxazoline derivatives, and as a result are not subject to prenylation; 
moreover, the prenyltransferase homolog in the pat  pathway, PatF, is apparently inactive 
as a prenyltransferase in vitro. Given the activating effect of the mevalonate pathway 
with the tru !F1 pathway, we speculated that mbi-coexpression would similarly increase 
production of patellamides (as observed for unprenylated patellins). Surprisingly, we 
found that this was indeed the case: patellamide production was increased in proportion 
to the concentration of added mevalonate, despite the complete lack of prenylation in pat 
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pathway products (Figure 3.6). In the presence of cysteine, pat production is minimal and 
often undetectable and is increased to robustly detectable levels upon mbi-coexpression.  
 The above results suggest that the beneficial effect of mevalonate pathway 
expression on cyanobactin production may not be entirely exerted through the pathway 
itself. Rather, its effect may be at least partly indirect, acting through other metabolic 
pathways that may benefit from extra isoprenoid precursors. Channeling the precursors 
into these pathways would conceivably require longer precursors such as GPP and FPP, 
which would require both DMAPP and IPP for elongation. 25 
 
 
Figure 3.6. Increase in production of patellamides in the presence of mevalonate pathway 
and external mevalonate. Y-axis shows the ratio of compound peak area to the internal 
standard. Column A) pat, B) pat + 5mM cysteine, C) pat/mbi + 5mM cysteine, D) 
pat/mbi + 5mM mevalonate, E) pat/mbi + 5 mM cysteine + 5 mM mevalonate, F) pat/mbi 


























































































To test whether different isoprenoid species would exhibit defined effects in compound 
production, we co-expressed tru with three different versions of the mevalonate pathway: 
mevb, mbi, mbis, which convert mevalonate to IPP, DMAPP, and FPP, respectively. 
mevb lacks the isopentyl diphosphate isomerase, idi, for the conversion of IPP to 
DMAPP. We verified that the different expression strains contained these pathways by 
restriction digest of the overnight seed cultures. All three sets of mevalonate pathway 
enzymes, in the presence of cysteine and mevalonate (20 mM), increased compound 
production relative to controls (i.e, tru pathway only and empty plasmid pBBR)  (Figure 
3.7). Tru/mevb expressions yielded higher proportions of monoprenylated patellin 2, 
conceivably a result of the lack of idi to supply DMAPP for prenylation. The increase in 
tru/mbis might indicate that longer isoprenoid precursors could in part be responsible for 
the unexpected effects of the mevalonate pathway on cyanobactin expressions.  
 
Effects of the mevalonate pathway coexpression on growth 
 To determine how the additives cysteine and mevalonate affect growth, we 
measured the growth (OD600) of E. coli throughout the 5-day expression. Tru only and 
tru/pBBR expressions in the presence of cysteine, mevalonate, or both displayed similar 
growth patterns with a sharp log phase starting at 10 to 15 hours (Figure 3.8A) post 
inoculation. Without any additives, tru/mevb, tru/mbi, and tru/mbis expressions entered 
log phase at a similar time as controls (A and B, Figure 3.8) but reached a lower OD600 in 
stationary phase (Figure 3.8C-E), perhaps reflecting the burden of expressing additional 
enzymes. Cysteine in general did not affect growth measurably, nor did mevalonate.  
However, in the presence of mevalonate pathway enzymes and both additives (Figure 
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Figure 3.7. Increase in production of patellin 2 in the presence of mevalonate pathway 
variants. Y-axis shows the amount of compounds in mg/L . Expression conditions : A) 
tru B) tru/pBBR C) tru/ mevb D) tru/mbi E) tru/mbis.  Columns 1-5, no additives; 
columns 6-10, with 5 mM cysteine; columns 11-15, with 20 mM mevalonate; columns 
16-20, with 5 mM cysteine and 20 mM mevalonate. 
 
 
3.8C-E), growth was clearly altered, characterized by a long lag phase after inoculation.  
 
Activity of patellin 2 on DRG neurons  
 With a method to supply meaningful quantities of cyanobactins in hand, we 
sought next to study their bioactivity. While many cyanobactins have been reported to be 






antibiotic assays.26  Their ecological function within ascidians or free-living 
cyanobacteria remains unclear, 26 though a variety of hypotheses have been put forward, 
ranging from settlement inhibitors of competing organisms to antipredation defense.27   
To expand the range of potential pharmacological applications of cyanobactins, we chose 
to screen natural cyanobactins in a high-content phenotypic screen on mice dorsal root 
ganglion (DRG) neurons, which, given the breadth of the assay, has been described as a 
‘constellation pharmacology’ approach.28,29  In particular, the assay measures calcium 
influx into individual DRG neurons in a heterogenous population using a fluorescent 
probe, and can distinguish a broad variety of responses to compounds, including ion-
channel agonists, antagonists, and a diverse array of other receptor ligands.28  The goal 
was first to identify natural cyanobactin leads that exhibited neuroactivity on a subset of 
the heterogenous DRG population, and from there to use our heterologous system to 
supply compounds for follow-up studies into molecular mechanisms of action, and 
structure-activity relationships.   
 In our initial screen, we tested compounds 2, 3, 6, patellamide C and a mixture (7 
and 8), ulithiacyclamide12 (9), lissoclinamide 330 (10), lissoclinamide 431 (11), and 
trunkamide 32 (12) at 10 µM concentrations (Figure 3.9). We observed clear activity for  
compounds 3 and 9. Specifically, application of 3 caused changes in the [Ca2+]i  shown 
through enhanced response to KCl (25 mM) in some cells as well as direct perturbation 
of the baseline in others (Figure 3.10A). Compound 9 similarly enhanced the KCl-
induced [Ca2+]i   upon application. Interestingly, compound 2 was inactive in this assay 
despite differing from 3 by only a single prenyl group. We chose to pursue 3, as its 
production was already optimized in our heterologous expression system.  
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Figure 3.9. Structures of cyanobactins screened in the DRG assay. Compounds were 
assayed at 10 µM concentrations. 2,3,and 6 are shown in Figure 3.3B. 
 
 To rule out the possibility of contamination by another extract component, we 
tested 3 purified from both the coral reef animal Lissoclinum patella and from 
recombinant E. coli expression. We observed that both were active and showed the same 
[Ca2+]i  phenotypic response in the same cells (Figure 3.10C). Further dose-response 
experiments separated the cells into subpopulations according to their sensitivity to 3: in 
group A were cells that were dose-responsive showing an indirect and increasingly 
enhanced [Ca2+]i signal from 3 µM 3, in B were cells that were only affected at a high 
dose (30 µM) with indirect amplification of [Ca2+]i signal, and in C were cells that were 
directly affected by a firing response at 30 µM (Figure 3.10D). The cells were also 






































































(nociception, P2X), and capsaicin (heat, TRPV1). Table 3.2 shows the percent of cells, as 
classified by their response to 3 above, that responded to the application of the 
pharmacological agents. Cells from subpopulations B and C were highly correlated with 
TRPV1, indicating that 3 could affect nociceptors. The different responses in the sub-
populations further suggests that 3 may act on multiple cell types that differ in the 
expression levels of its molecular target.!
 
Discussion 
 Natural products are indispensible sources of drugs given their complex scaffolds 
and often potent activities against novel biological targets.33 Most natural products, 
however, are left undeveloped because we lack a means to supply them.  The engineering 
of natural product biosynthetic pathways into heterologous hosts has the potential to  
address these challenges by improving the supply of natural products, and also allowing 
the production of derivatives through simple genetic engineering.34 However, many  
 
Table 3.2. Summary of calcium imaging experiments with 3. Values are presented as 
percentage of cells that exhibited a type of response (A-C) that are sensitive to 
pharmacological agents (columns 2-4). Response types to 3 are classified as: A, dose 
responsive from 3 mM to 30 mM; B, indirect through amplification of KCl response; C, 
direct effects on the baseline [Ca2+]i. 
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heterologous expression experiments are conducted primarily for the purposes of 
verifying bioinformatics predictions of compounds, and thus are unlikely to result in 
consistent and robust supply of compounds.  Thus, the continued development of 
methods to improve yields in heterologous expression is essential to ease this bottleneck 
in the search for medicinal natural products.  
 Here we have described a method for the improvement of the heterologous 
production of cyanobactins, resulting in a stable, 100-fold boost in titer. This increase 
was brought about through a combination of media optimization and improving the 
supply of endogenous precursors through the coexpression of an independent 
biosynthetic pathway. In particular, we have demonstrated that compound production is 
synergistically increased by the supplementation of the amino acid cysteine and by 
isoprene precursors supplied by the mevalonate pathway.  
 The effect of mevalonate pathway expression on cyanobactin yield is particularly 
interesting as we initially intended to increase DMAPP levels to support complete 
prenylation of cyanobactins. Although we observed a modest shift in the ratio of 
prenylated/unprenylated compounds upon mevalonate pathway coexpression, a greater 
effect was observed in the increase of the total amounts of compounds, including those 
that were unprenylated. We found that this effect depends on the concentration of the 
added mevalonate.   
 The increase in the amount of all the derivatives indicates that the increase in 
production is not directly related to compound prenylation. Indeed, knocking out the tru 
pathway prenyltransferase, truF1, showed that the levels of unprenylated compounds 
were still increased by mevalonate in a dose-dependent manner. Further, we have shown 
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a mevalonate-dependent increase in the production of the patellamides, which do not 
contain prenyl groups. Thus, it is likely that the effect of mev-coexpression is exerted 
through multiple channels, some of which act indirectly on the pathway enzymes. For 
example, excess isoprenoids could be channeled into pathways that in turn affect growth 
and fitness of the cells under conditions of compound production that are otherwise 
stressful. Indeed, through coexpressions with tru/mbis, we showed that channeling the 
isoprene intermediates into longer units also maintained compound production. 
 Given the growing importance of tools such as the mev pathway in metabolic 
engineering efforts, our results highlight the often unpredictable and nonadditive effects 
that can result.  To this end, we are currently investigating the metabolome of E. coli 
under these different conditions with the goal of identifying the pathways and metabolites 
that change in response to mev coexpression. One other intriguing feature of our results is 
that the beneficial effects of mev-coexpression are dependent on the presence of cysteine. 
From our quantifications of many different experimental sets, we determined these 
effects are not merely additive. Cysteine by itself consistently increases compound 
production, while mevalonate exerts a significant effect only in the presence of added 
cysteine.  
 Altogether, the unanticipated effects of the mevalonate pathway on cyanobactin 
production opens new possibilities for heterologous production of RiPPs in E. coli, as 
even unprenylated cyanobactins were increased upon mev coexpression.  To our 
knowledge, this is the first demonstration of such an ‘off-target’ effect of mev pathway 
coexpression, in which the titer of non-terpenoid natural products is observed to increase.  
Serendipity aside, this study also emphasizes the combination of both empirical (the 
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discovery of cysteine as an additive) and rational (supply of isoprene for full prenylation) 
approaches in the optimization of cyanobactin production.  
 Having established a high-yielding expression system of cyanobactins, we sought 
to readdress one of the fundamental goals of natural product discovery and engineering, 
that of discovering novel bioactivities.   Thus, we applied several cyanobactins to a broad 
phenotypic assay, and uncovered the activity of patellin 2 in provoking action potentials 
in DRG neurons.  Patellin 2 was first isolated and characterized from L. patella ascidian 
in 199035; however, no biological activity has been reported on this compound until now. 
Although the neuronal subtype specificity and molecular target of patellin 2 is the subject 
of ongoing work, based on comparison of both expressed and natural compounds, we 
were able to establish that patellin 2 is active affecting different types of nociceptors.  
This represents the first DRG activity reported for a cyanobactin.  These results 
emphasize the importance of broad pharmacological screens since the native targets for 
the vast majority of natural products are unknown, and further underline the potential of 
small, highly modified cyclic peptides as neuroactive agents.  
 In summary, we have established a method for the highest titer of cyanobactins so 
far. We have discovered, serendipitously, the positive effects of mevalonate pathway 
expressions to cyanobactin production. This method is the first step in removing the 
bottleneck for the development of cyanobactins as pharmacological and therapeutic 





Materials and methods 
Plasmids and strains 
 Plasmid pTru-SD contained the tru operon in Topo vector. tru contained the 
precursor peptide gene TruE2, which encodes for patellin 2 (3) and patellin 3 (6) in the 
core peptides. pMEVB, pMBI, and pMBIS, containing the second half of the mevalonate 
pathway were obtained from Addgene (plasmids 17819, 17816, and 17817, respectively). 
pMEVB contains ERG12, ERG8, MVD1; pMBI has the pMEVB genes but with idi 
appended after MVD1; pMBIS is pMBI with additional ispa. 24 Empty plasmid pBBR 
with a modified multiple cloning site was constructed from pMBI. pMBI was digested 
with KpnI and SacI. The vector backbone piece was ligated with a small piece of DNA 
constructed from overlapping primers to create an expanded multiple cloning site 
(forward: 5’ AGTGTACAGGGCCCCCCCTCGAGGGTATCGATAAGC 
TTGATATCGAATTCCTGCAGTAGGAGGAATTAACCCATATGTC, reverse: 
GATGAGCT CCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGG 
GTACCATGGACATATGGGTTAATTCCTC). pPat (pat) contains the patellamide 
pathway genes that were codon-optimized for E. coli. pat is in Topo vector. For the truF1 
knockout experiments, modified tru expression plasmid was made from fragments of the 
previously described vector,17 containing truA-D and truG and gBlocks containing truE, 
F1, and F2 (IDT, Coralville, IO). The gene sequences in the gBlocks were codon-
optimized for expression in E. coli. This plasmid was assembled by recombination in 
Saccharomyces cerevisiae BJ4741 using previously described methods. 17 truDF1 was 
made by Gibson assembly 36 of PCR products containing most of the modified tru 
plasmid in two pieces. The first piece consisted of half of the plasmid backbone and the 
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first part of the tru pathway (truA-E ). The second piece contained the end of the tru 
pathway (truF2 and truG) and the other half of the plasmid backbone. All vectors were 
partially sequenced to confirm that the pieces had been ligated correctly. All pathways 
were under the control of lac promoter and expressed constitutively in DH10B cells. 
 
Chemicals and other materials 
 L-cysteine hydrochloride was obtained from Amresco (Solon, OH).  Ampicillin 
and tetracycline were obtained from Sigma-Aldrich (St. Louis, MO). All solvents used 
for silica open column chromatography, HPLC, and HPLC/MS analyses were obtained 
from Fisher Scientific (Pittsburg, PA). Lissoclinum patella samples that were used for 
isolation of standards 3 and 6 were collected in Papua New Guinea with proper collection 
permits.  
 
Fermentation conditions and compound expressions 
 Plasmid pTru-SD1 (tru) was transformed alone or co-transformed with pBBR, 
pMEVB (mevb), pMBI (mbi), or pMBIS (mbis) (Martin 2003). The resulting clones were 
then inoculated into liquid 2xYT broth (6 mL) in 24-well plates with the addition of 
appropriate amount of antibiotics (ampicillin: 50 mg/mL, tetracycline: 5 mg/mL), and 
grown overnight. Growing seed cultures (0.2% v/v) were then inoculated into fresh media 
containing antibiotics described above. Cysteine (5 mM) was added upon inoculation of 
expression cultures. Mevalonolactone (Sigma-Aldrich, St. Louis, MO) was hydrolyzed to 
mevalonate according published methods (Martin 2003) and was also added to the 
expression cultures at inoculation (5, 10, 20, 40 mM final concentrations). The cultures 
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were allowed to shake at 150 rpm, 30 °C for 5 days after which the cells were harvested 
by centrifugation at 4000 rpm, washed with saline solution (100 mM NaCl), and 
extracted with acetone (4 mL). The acetone extracts were then dried to yield the organic 
extracts for each 6 mL culture. In labeling experiments, 13C mevalonate (1 mM) (Sigma- 
Aldrich, St. Louis, MO) was added at the beginning of the expressions as described 
above. To express patellamides, pat was co-transformed pMBI and processed as 
described above.  
 
Isolation of patellin 2 from E. coli expressions 
 Overnight seed cultures of E. coli harboring tru/mbi were grown under 
appropriate antibiotic selection and inoculated into 1L 2xYT broth with antibiotics, 
cysteine (5 mM), and mevalonate (10 mM). The broth was distributed into 24 well plates 
containing 6 mL per well and grown for 5 days at 30 °C while shaking at 150 rpm. The 
cultures were harvested as described above, and the cells were extracted repeatedly with 
acetone. The combined acetone fractions were dried and fractionated by silica open 
column chromatography using previously described gradient and methods .10  Fractions 
were analyzed by HPLC-MS for the presence of cyanobactins, and the compound 
containing fractions were subjected to reverse phase HPLC fractionation on an Eclipse 
XDB, 9.4 x 250 mm, 5m C18 column (Agilent Technologies, Santa Clara, CA) using the 
following solvent gradient: 5% B to 100% B (0-30 minutes), 100% B (30 to 40 minutes), 
and 100% to 5% B (40 to 45 mins); Solvent B consisted of acetonitrile and solvent A 
consisted of water. A flow rate of 2.5 mL min-1 was used. Compound 3 was purified on a 
Luna, 4.6 x 250 mm, 5 !m C18 Column (Phenomenex, Torrance, CA) using the solvent 
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gradient: 80% B to 94% B (0-15 minutes), 94% B (15-17 minutes), and 94% to 80% B 
(17-20 minutes), at a flow rate of 1ml min-1; Solvent B consisted of acetonitrile and 
solvent A consisted of water.  
 
Quantification by proton NMR 
 1H NMR was used to quantify purified patellin 2.  This information was used as 
the basis for the HPLC/MS calibration curve as well as for bioactivity assays. An external 
standard curve was made using the different amounts of 1,4-dinitrobenzene (Sigma- 
Aldrich, St. Louis, MO) using described methods. Briefly, 2-fold dilutions (1.2mM to 
79.3 mM) of 1,4-DNB in DMSO-d6 (Cambridge Isotope Laboratories Inc., Tewksbury, 
MA) were prepared in uniform 3 mM Kontes precision NMR tubes (Sigma- Aldrich, St. 
Louis, MO). 1H NMR for each DNB sample was acquired on a Varian Inova 500 
instrument (Agilent Technologies, Santa Clara, CA) with 32 scans using an 18 s 
relaxation delay (d1) as calculated from T1 using signal inversion. The integrals of the 
four DNB protons were obtained and used as the Y-values for the calibration curve 
(Figure 3.11). Patellin 2 was prepared using the same DMSO-d6. The 1H spectrum of 
patellin 2 was obtained using 32 scans and 4 s d1, which was determined as described 
above. Signals from a methyl protons of the valine residue were integrated and the values 
were compared with the external standards.  
 
Quantification of cyanobactins from different expressions using HPLC/MS 
 Extracts were dissolved in methanol (500 mL) and analyzed by HPLC-ESI-MS 
using a Waters Micromass ZQ mass spectrometer. Samples were injected at uniform  
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Figure 3.11. 1H NMR calibration curve using 1,4-Dinitrobenzene. 
 
volumes (40 mL). A synthetic derivative of a heptamer cyclic peptide (7, Figure 3.12B) 
was used as an internal standard in all HPLC/MS analyses. The extracts were analyzed on 
a Zorbax Eclipse Plus 4.6 x 150 mm, 5 !m, C18 column (Agilent Technologies, Inc., 
Santa Clara, CA) using the following solvent gradient: 10% B (0-2 minutes), 10% B to 
100% B (2-20 minutes), 100% B (21 to 30 minutes), and 100% to 10% B (30 to 35 mins). 
Solvent B consisted of acetonitrile with 0.05% (v/v) formic acid; solvent A consisted of 
water with 0.05% (v/v) formic acid. The peaks of interest were selected from the 
chromatograms and the resulting peak areas for each compound in the extract were 
obtained. The ratio of the peak area of the compound of interest to the peak area of the 
internal standard was then taken in each sample and the amount of each compound was 






















Figure 3.12. A) LC/MS calibration curve of patellin 2. Y-axis represents the ratio of the 
peak area of different amounts (X-axis) of patellin 2 to the internal standard (panel B). B) 
structure of E8 internal standard. 
 
purified patellin 2 (Figure 3.12a). All expressions were done in triplicate. Around 70  
independent expression experiments (average of 8 different conditions in each set) were 
done over the course of optimization, confirming the reproducibility of the results. 
 
Growth experiments 
 Samples were grown in 6 mL volumes, in quadruplicates sets, in 24-well plates as 
described above. Aliqouts (100 mL) were drawn and transferred to a 96-well plate 
containing 2xYT (100 mL) and the OD was measured on a microplate reader. OD600 was 
measured every 3-4 hours for 120 hours. The remaining cultures were extracted for 


















































Calcium imaging on mouse dorsal root ganglion (DRG) cells 
 The DRG assay has been described previously.37 28 Briefly, the cells in their 
growth media were loaded with Fura-2-AM for 1 h at 37° C and incubated further for 30 
minutes at room temperature. The media was then replaced with a CSF for calcium 
imaging at room temperature. Changes in cytosolic calcium concentration were 
monitored over time through the ratio of fluorescence intensities at 510 nm obtained from 
intermittent (typically once every 2 s) excitation by 340-nm and 380-nm light (labeled as 
“ 340/380 nm ” in the y-axis of calcium-imaging figures. The increase or decrease in 
calcium levels is represented by an upward or downward deflection of the trace. High 
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ABSTRACT: The cyanobactin ribosomal peptide (RP)
natural product pathway was manipulated to incorporate
multiple tandem mutations and non-proteinogenic amino
acids, using eight heterologous components simultaneously
expressed in Escherichia coli. These studies reveal the potential
of RPs for the rational synthesis of complex, new small
molecules over multiple-step biosynthetic pathways using
simple genetic engineering.
■ INTRODUCTION
A major goal of synthetic biology is to engineer the synthesis of
organic compounds in vivo.1 Ribosomal peptide (RP) natural
products provide a relatively simple starting point for such
studies. In RP pathways, short precursor peptides are
ribosomally translated and subsequently modified by enzymes
into complex natural products.2 The products of RP pathways
are often elaborately tailored, so that in extreme cases (such as
pyrroloquinoline quinone),3 the compounds are no longer
easily recognizable as arising from amino acids. A further
advantage is that RP biosynthetic enzymes generally exhibit
relaxed substrate specificity.2,4 Because of this, often sequence-
identical enzymes are capable of accepting a vast array of
peptide substrates.5,6 Here, we seek to develop methods for
making unnatural RPs and to better understand substrate
selectivity of RP pathways. In so doing, we hope to enable
synthetic biological approaches to the directed creation of
diverse structures using ribosomally translated starting
materials. In addition to these design and synthesis goals,
RPs are often potently bioactive against diverse targets, and
thus understanding and manipulating individual RP pathways is
a major goal in its own right.
In Nature, RPs occupy many different chemical classes, with
many different posttranslational modifications.2 These classes
have been examined by observing natural variation, as well as by
manipulating biosynthetic genes and by performing biochem-
ical and substrate analyses. Observation of Nature indicates that
at least several pathways handle extremely diverse substitutions.
For example, >60 cyanobactin genes have been isolated from
symbiotic bacteria living in marine animals, where the enzymes
are essentially identical yet the products are extremely
sequence-diverse.5 RP biosynthetic genes have already been
modified in several ways, most of which have focused on point
mutations of pathways that require one or two enzymatic steps
for maturation.7−10 Single or multiple mutations have been
introduced into lantibiotics, and more recently, multiple
tandem substitutions have been introduced into lasso
peptides.12 These mutations are usually aimed either to
improve the known biological activity, or occasionally even to
design a new biological activity.13 A few mutational studies have
focused on complex pathways with multiple biosynthetic
steps.5,14,15 For example, the integrin-binding RGD motif has
been introduced into cyclic peptides using cyanobactin pathway
enzymes5 and lasso peptide enzymes.13 However, overall the
field is still distant from achieving the goal of wholesale
introduction of new motifs at will, especially in the more
complex, multistep pathways.
A further goal in this field has been to incorporate motifs
other than the canonical 20 amino acids into the backbone of
RPs. Since the posttranslational enzymes exhibit extremely
broad substrate tolerance, such changes would greatly extend
the capabilities of RP pathways in synthetic biology. In many
cases, synthetic substrates have been fed to RP enzymes in
vitro. A potentially more powerful approach from the synthetic
biology point of view is to simply incorporate non-
proteinogenic amino acids in vivo. Indeed, non-proteinogenic
amino acids have been added to RPs in vivo, although only in
single-step processes involving lanthionine synthase or
inteins.16,17 Incorporation of such “unnatural” amino acids is
considered desirable because it provides unprecedented control
over chemical structure in vivo.
Here, we sought to explore the mutation and addition of
non-proteinogenic amino acids with a much more complex
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pathway to cyanobactins, which are highly modified, macro-
cyclic RPs.18,19 Cyanobactins usually have four types of
posttranslational modifications, with up to eight individual
modified amino acids, encompassing up to 18 separate
biochemical transformations (Figure 1). Heterocylization and
oxidation, N- and C-terminal proteolysis, macrocyclization, and
prenylation lead to final natural products.5,6,20−24 In the pat and
tru cyanobactin pathways, core sequences encoding six- to
eight-amino acid cyclic peptides are contained in defined
cassettes in a precursor peptide (Figures 2 and 3).5,6 The 18−
24 nucleotide hypervariable regions are flanked by invariant
sequences that direct enzymatic modification.5 Thus, the
synthesis of new compounds requires only simple genetic
engineering.6
In the tru pathway, originally cloned from uncultivated
symbiotic bacteria in a marine animal, a ∼70 amino acid
precursor peptide (TruE) is synthesized that encodes two
cyanobactins (Figure 1).6 Heterocyclase TruD acts on Cys
residues in specific positions, synthesizing thiazoline.23
Subsequently, TruA protease removes the leader sequence
and affords two free N-termini for macrocyclization.22 TruG
protease cleaves C-terminal recognition sequences in tandem
with macrocyclization to provide small, cyclic peptides.20,22,23
Finally, TruF1/TruF2 decorate the cyclic peptides with
isoprene on specific Ser and Thr residues.24 In this manner,
we have previously successfully produced coral reef-derived
marine natural products patellin 2 (1), trunkamide (2) and
patellin 3 (3) by heterologous expression in E. coli. Optimal
production of wild type compounds 1−3 requires five days,
emphasizing the complexity of the process.25
Some ascidian cyanobactins, and especially 2, are considered
as potential anticancer leads.26,27 Cyanobactins in the
patellamide class are potent inhibitors of drug efflux.28,29
Therefore, synthesis of derivatives in the manner described
herein is expected to lead to bioactive molecules that are
amenable to drug development. More importantly, as shown by
the integration of RGD motifs into cyanobactins, we are
interested in exploring the mutability of these pathways because
they can be used to install desired or random features into
natural product-like structures, using simple genetic engineer-
ing.
■ RESULTS
Cloning and Expression Strategy. The pUC-based
vector ptru-SD1 (Symbion Discovery, Inc.) encodes tru
biosynthetic enzymes and a copy of the precursor peptide
TruE1, encoding patellins 2 (1) and 3 (3), under control of the
lac promoter (Figure 2). To encode new cyanobactin
derivatives, we constructed a second vector (ptruE), which is
compatible with ptru-SD1 and can be used for coexpression
experiments. ptruE contains only the truE gene, under control
of the lac promoter. The first cassette of ptruE encodes 3, while
the second cassette can be varied to synthesize novel
compounds (Figures 1 and 2, Tables 1 and 2). In this system,
compounds 1 and 3 are always synthesized in E. coli and serve
as internal controls to show that the tru pathway is functional.
In addition, because both plasmids are under control of the
constitutive lac promoter, no induction is necessary, and
optimum production requires five days of fermentation at 30
°C. The general system was previously optimized, and we
showed that addition of inducers or repressors serve to decrease
yields.25 Thus, after five days without induction, internal
controls 1 and 3 are produced, and possibly new derivatives
encoded on ptruE.
In this study, the sequence in the second cassette of ptruE
was manipulated using cloning, while the first cassette was kept
constant to produce positive control 1. The fidelity of this
process was determined by gene sequencing, where the ptruE
derivatives were Sanger sequenced. Thus, each E. coli
expression clone encoded all necessary tru enzymes, internal
standards leading to production of 1 and 3, and a gene for one
of the new compounds 4−22. In expression experiments,
production of 1 and 3 would indicate that enzymes were
functional and active and would also provide internal
calibration for yield determination, while new compounds
would be expressed only if the sequences were substrates for all
tru enzymes.
Figure 1. Biosynthesis of tru pathway derivatives in Escherichia coli.
Numbered components indicate eight individual elements including
enzymes, tRNA, or precursor peptide (TruE variants) that are required
for synthesis of mature natural products. The orthologous tRNA and
amino acyl tRNA synthetase components required to introduce non-
proteinogenic amino acids are shown in blue. Enzymes from the tru
pathway are indicated in orange. The precursor peptide TruE is shown
with a helical, 35-amino acid leader sequence indicated schematically.11
X indicates any amino acid.
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We constructed mutants based upon known natural
products, compounds 1-3, which we previously identified in
uncultivated symbiotic bacteria living in marine animals and
expressed successfully in E. coli.6 In addition, 1−3 are hexa-,
hepta-, and octameric, respectively, so that mutations explored
a range of different substrate and product sizes. We sought
primarily to make a series of mutants that would broadly
explore sequence selectivity of the tru pathway. Out of the
constellation of possible mutations that could answer this
question, we picked representative derivatives that were also
interesting to us because they helped to answer other pressing
scientific questions about the cyanobactins pathways (see
Discussion). Thus, the results of these experiments would have
broad application in synthetic biology and specific application
to understanding this interesting group of natural products,
which are very broadly distributed.
Chemical Analysis and Isolation. After five days of
fermentation, the pelleted E. coli cells were extracted with
methanol. The organic extracts were partially purified and then
analyzed using HPLC-ESI-MS. In all cases, heterologous
expression of control compounds 1 and 3 was confirmed,
with the compounds eluting with the same profile as standards
of authentic 1 and 3, which we obtained from a marine animal
Figure 2. Expression strategy. Enzymes and two control molecules are synthesized constitutively from the vector ptru-SD1 (top). An internal control
sequence and a variable region, that can lead to peptide libraries, is synthesized from ptruE (bottom). Optionally, non-proteinogenic amino acids can
be included using a third vector, pEVOL (right).
Figure 3. Expression of mutant cyanobactins. E. coli cultures
expressing 20 (left) and 15 (right) were harvested and analyzed by
FT-MS. Extracted ion chromatograms showed that each culture
expressed control compounds 3 (A) and 1 (B). In cells containing
plasmids encoding 20, compound 20 could be detected (C), but not
15 (D), nor any other cyanobactin 4−22. Similarly, in cells encoding
15, only compound 15 (D) but not 20 (C), nor any other
cyanobactin, could be detected. Thus, each experiment contained
two internal positive controls and 19 external negative controls.
Table 1. Design Strategy for Mutants
a.Wild-type compounds 1−3 were mutated, with changes to wild type
shown in bold. b.Compounds were designed based on known natural
products that had not been previously expressed, or based on
sequences identified by genome mining (see Discussion for full
description). c.Macrocylic ring size, in number of amino acids.
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as previously described (Figure 3).6 We previously showed that
isoprene is readily lost from Ser and Thr cyanobactin
derivatives under standard MS conditions.25 Thus, loss of
isoprene reliably indicates the formation of mature cyanobac-
tins, and this loss is not observed in any natural E. coli
compound. In addition, we observed ions representing a total
of 16 out of 22 recombinant cyanobactins. A table was
constructed in which the recombinant sequence determined by
DNA sequencing was used to predict a unique mass for the new
cyanobactin and for the loss of one or more isoprene groups
from each predicted new compound. The prediction ions were
only observed in expression experiments involving the
sequence in question, and not in other experiments, so that
we essentially had 19 negative control experiments for each
compound produced (Figure 3). In addition, if prenylated, the
ions readily fragmented to lose the predicted numbers of
isoprene groups, in contrast to all other E. coli metabolites.
Finally, in most cases we observed incomplete prenylation, so
that mono-, di- and sometimes triprenylated derivatives were
formed in E. coli. In total, we identified 21 new compounds,
produced in E. coli, that matched the masses predicted from
DNA sequencing.
To further confirm the expression of the predicted
compounds, they were subjected to analysis by high-resolution
LC-FT-ICR-MS/MS, using previously established meth-
ods.24,25,30 The ions did indeed reflect the predicted
compounds, to <2 ppm value, with loss of isoprene observed
in MS/MS. When no isoprene was present on a compound, the
fragmentation pattern reflected the sequence of the peptide.
Thus, because of the numerous internal and external controls,
the sequencing data, and the well-validated MS data, we had
high confidence about the identity of expressed products.
Finally, to further demonstrate that the recombinant
compounds were successfully produced, we selected a set of
representative compounds, 1, 10, and 14, for NMR analysis.
These compounds were purified to homogeneity from the E.
coli cell pellets, and their 1H NMR spectra were obtained
(Figures S4−S7 and Table S1 in Supporting Information [SI]).
In all cases, the NMR spectra matched those predicted for the
new compounds, showing that they were the predicted
cyanobactins.
Expression of Mutant Cyanobactins. Hexameric patellin
2 (1) was manipulated to create compounds 4−8, which were
triple or quadruple mutants of the wild type sequence (Tables 1
and 2). The triple mutants (4−6) were successfully synthesized
in E. coli, while the quadruple mutant 7 was not detected. We
previously reported successful expression of 4,31 while all other
compounds 5−22 are reported here for the first time.
In contrast to hexapeptide derivatives, for which diverse
sequences are known, there are few known heptameric tru
derivatives. Therefore, we created single-point mutants 13−15
of heptameric trunkamide (2). Only 13 and 14 were
successfully processed in vivo. Pentuple mutants 16 and 17
were also not formed. Octapeptide selectivity was examined by
synthesizing double mutants 19 and 20, pentuple mutant 21,
and hextuple mutant 22. Surprisingly in comparison with our
experience with heptapeptides, 19, 20, and 22 were
synthesized.
If more than one prenylation event was possible, we detected
both singly and multiply prenylated derivatives. (For derivatives
9, 11, and 12 we detected only monoprenylated compounds,
while for 18, no prenylation was detected, indicating that the
molecule was not a substrate for TruF1/F2.) This was true
even for the wild type compounds in E. coli, showing that
complete prenylation is a limiting step in this host. We also
observed this pattern in systems that produce a lower
cyanobactin yield, indicating that it may be an intrinsic pathway
property and not linked to the amount of dimethylallylpyr-
Table 2. Expression Yields in E. coli
aYields shown are for new compounds, compound 1, compound 3, and the total of all compounds found in a single expression experiment. Yields
are reported as fully prenylated/−1 prenyl; i.e., for compound 4, 8.8 μg L−1 of diprenylated and 16 μg L−1 of monoprenylated compounds were
produced. bRel yield (%) indicates the total amount of new compounds, divided by the total amount of compound 1, found in an individual sample
(times 100 to give percentage). This gives the most accurate assessment of relative yield of new compounds between experiments. cOnly the
nonprenylated 18 was identified, indicating that 18 is not a substrate for TruF1/F2.
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ophosphate available in E. coli. In known natural products,
TruD heterocyclase only modifies the C-terminal Cys residue.
However, we previously showed that TruD modifies internal
Cys residues in unnatural substrates in vitro.16 The primary
sequence of compound 22 was derived from the pat
biosynthetic pathway,23 in which all Cys and Thr/Ser residues
are heterocyclic. However, in 22, two Cys residues were
heterocyclic, but the two Thr residues were prenylated. This
reveals that the pat and tru pathways may be hybridized to
create diverse new derivatives.
Incorporation of Non-Proteinogenic Amino Acids. We
sought to incorporate non-proteinogenic amino acids using an
orthogonal tRNA/aminoacyl-tRNA synthetase (tRNA/aaRS)
pair that incorporates a specific unnatural amino acid in
response to nonsense or frameshift mutation.24 First, we
showed that non-proteinogenic amino acids could be
incorporated into the TruE precursor peptide. The plasmid
pEVOL-pAcF which can specifically incorporate The non-
proteinogenic amino acid p-acetyl-phenylalanine (p-AcF) was
coexpressed with plasmids encoding truE derivatives, which
were C-terminally His-tagged and in which each position in
patellin 2 was individually mutated to the amber codon TAG
(Figure S3, SI). p-AcF was added to the fermentations. SDS-
PAGE of Ni purified lysates revealed that p-AcF could be
incorporated in all six positions in the context of a precursor
peptide (Figure S3, SI). These experiments showed that there
was no problem in placing non-proteinogenic amino acids into
the TruE precursor peptide backbone, in the absence of
modifying enzymes. However, we still needed to determine
whether the modifying enzymes could accept the highly
unnatural amino acids and carry them through 4−5
biosynthetic steps to the mature unnatural natural products.
We therefore attempted to coexpress this same system with
ptru-SD1 and other ptru vectors. However, in extensive initial
experiments with non-proteinogenic amino acids, including p-
AcF and others, could not be incorporated into cyanobactins
using standard conditions. Several enzymes must be temporally
coordinated in order to produce the mature cyanobactins over
the course of our five-day fermentation. In extensive previous
work with this pathway, changing the coordinated regulation of
this pathway in any way severely impacted product yield.25 For
example, even providing each gene in the eight-gene tru
pathway with its own heterologous promoter was unsuccessful.
It is clear that the complex regulation of this multistep pathway
remains poorly understood.
Previously, it was noted that incorporation of non-
proteinogenic amino acids into single proteins over relatively
long (14 h) induction times could be optimized with two
copies of aaRS, one of which was constitutive and one of which
was inducible with arabinose.32 In fact, ∼1 day is the longest
expression period to which this methodology has been
previously applied, to the best of our knowledge. The five-
day fermentation time for heterologous expression of tru is
much longer than this, and in addition, the complex pathway
regulation of tru is poorly understood. Therefore, we reasoned
that adjustment of aaRS induction might improve cyanobactin
production. Specifically, we thought that constitutive expression
of aaRS might be better matched to the constitutive expression
of tru. The plasmid pEVOL-pCNF (which encodes a
polyspecific aaRS that incorporates a variety of Phe derivatives
but not Phe or Tyr to any significant extent)25 was used. We
varied expression of the arabinose-inducible copy of aaRS in
pEVOL-pCNF using different concentrations of inducer (L-
arabinose). Optimal incorporation of p-chloro-phenylalanine
was achieved in the absence of arabinose, while increasing
arabinose concentrations and thus the flux of aaRS
incrementally decreased product yield (Figure 4). With
optimized conditions in hand, pEVOL-pCNF was used in the
preparative synthesis of 9−12, in which Leu of patellin 2 (1)
was replaced with substituted phenylalanine derivatives, and 18,
in which Phe of trunkamide (2) was replaced with p-
bromophenylalanine (Figure 2 and Table 1). Out of the
many possible amino acids that might be incorporated into
engineered natural products using pEVOL-pCNF, we chose a
limited subset for this work not including p-AcF.
Yield Measurement. Yields were determined for all
heterologous expression experiments. First, purified 1 was
quantified by NMR integration using several different
concentrations of the standard, 1,4-dinitrobenzene,33 to give
an isolated yield of 260 μg from a 10-L fermentation. This
method is much more accurate than other methods for
microgram quantities of material, since it measures the relative
molar amounts of compound directly using a calibrant.
With a standard concentration of 1 available, we used known
concentrations of 1 as internal and external standards for
HPLC-ESI-MS experiments. These experiments used crude
fractions containing recombinant peptides, so that they much
more closely resembled the native production yield, and not
merely the isolated yield. For example, the area under the curve
was integrated to show that 1.7 mg of 1 was produced in the 10
L E. coli expression described above, but the isolated yield was
only ∼10% after several purification steps. An additional 1.3 mg
of the monoprenylated variant of 1 was also produced in this 10
L fermentation, leading to an overall yield of 3 mg of 1 variants.
Figure 4. Optimization of non-proteinogenic amino acid incorpo-
ration. Compound 10 was synthesized in E. coli and analyzed by LC-
ESI-MS. Optimum production was achieved in the absence of inducer
(arabinose), whereas higher concentrations of inducer completely
repressed synthesis. Two peaks are present because multiple
stereoisomers are present (the α-proton adjacent to thiazoline is
labile, and Pro undergoes cis−trans isomerization in this family).26.
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Because 1 was produced in all expression experiments
reported herein, the compound could also be used to estimate
the production level of other recombinant products. Yields of
most compounds were in the range of 1−170 μg L−1. (see
Table 1). Compound 2 was also present as an internal control.
A potential weakness of this method is that the relative
ionization efficiencies of the compounds are likely to differ.
However, the ratios were also compared to those achieved
using FT-ICR-MS, showing a consistent relative ratio of ions in
both methods. Moreover, in previous studies we have not seen
a large range of ionization efficiencies for these similar
compounds, indicating that the reported yields are good
estimates. The relative yields determined by MS were also
reflected in the isolated yields of 10 and 14.
■ DISCUSSION
In this study, we exploited the relaxed substrate selectivity of
the tru pathway to generate diverse mutants, despite the need
to go through a complex biosynthetic route. Although not all
derivatives can be made, this study shows that the tru
posttranslational machinery exhibits broad substrate tolerance.
We also report the first in vivo incorporation of non-
proteinogenic amino acids into multistep RP products. Notably,
control of six different enzymes, two precursor peptides, and a
tRNA molecule was required for synthesis of the reported
derivatives. Incorporated, non-proteinogenic amino acids were
successfully carried through a multistep pathway with 12
individual enzymatic transformations. This was accomplished
using eight enzyme tru domains encoded in six tru proteins,
whereas previously at most one enzyme with two domains has
been used.11 We expect that the methods here will be widely
useful in the synthesis of diverse RP derivatives encoding non-
proteinogenic amino acids.
A simple but important advance was the observation that
low-level, constitutive expression provides excellent incorpo-
ration of non-proteinogenic amino acids in natural product
derivatives. Prior to this report, the described technology had
been used routinely for incorporation of amino acids into
proteins, and a few reports exist for incorporation into short
peptides which undergo one further posttranslational mod-
ification. In these cases, the relative simplicity of the
heterologous expression systems made them very tolerant of
overexpression. In more complex systems, our data suggest that
producing too much of the aaRS (or any other component in a
complex pathway) is detrimental to efficient product synthesis.
There are now many different methods for implanting non-
proteinogenic amino acids into ribosomal peptides, some of
which involve changing the ribosomal code and some of which
involve synthetic modifications.34 Notably, recently the
concepts of multiple orthogonal substitution and residue-
specific substitution have been elaborated.35,36 The former
enables different non-proteinogenic amino acids to be
introduced into single peptides, while the latter enables all
residues of a specific type to be replaced by non-proteinogenic
amino acids. These methods are compatible with the ideas
developed here, but they will undoubtedly require some further
study to be applied to highly modified RPs, since so far they
have not been applied to such compounds.
In addition to exploring incorporation of diverse substitu-
tions, these experiments were designed to provide proof-of-
concept for key technological advances in marine natural
products, in five major areas. First, we have recently applied a
genomic method, in which we sequence genes from marine
animals and their symbiotic bacteria to discover new TruE-like
peptides.25,30 Subsequently, we find that the predicted peptides
are the major natural products found in whole animals.
However, the compounds are exceptionally limited in supply,
and at most micrograms are available from the natural sources.
As mentioned above, previously we expressed 4 to supply the
compound. Here, we wished to test the broad applicability of
the method by expressing compounds 4-6, which were first
identified by genomics and which were successfully made by E.
coli here.
Second, there were a series of previously described, rare
compounds from Nature, including mollamide (encoded by 16
and 17) and keenamide (encoded by 8).19,37 These compounds
were reported to exhibit interesting bioactivity but are in very
short supply. However, these compounds were not produced
by our tru pathway in E. coli, indicating that they are probably
synthesized by a different variation of the tru pathway found in
Figure 5. Compounds synthesized in this study. Yellow indicates wild-type compounds, while pink bubbles indicate mutations that deviate from wild
type. Hexa- (left), hepta- (mid), and octa- (right) peptide derivatives were synthesized using these methods. (*) Indicates compounds for which only
monoprenylated (9, 11, and 12) or nonprenylated (18) derivatives were identified. For all other compounds, both singly, doubly, and sometimes
triply prenylated products were identified.
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Nature. Third, we wished to express known marine animal
compounds, patellins 4 and 5 (19 and 20),19,38 for which we
had not previously found genes; these were successfully made.
Fourth, trunkamide is a potential anticancer agent of interest
because of its unusual profile in the National Cancer Institute’s
60-cell line panel. We tested its potential for derivatization by
making a series of point mutants, 13−15. Interestingly, addition
of a Ser led to a third prenylation event in 14, and 13 was
successfully produced. However, a simple Ser-Val substitution
in 15 led to loss of product.
Fifth, for compounds 21 and 22, we wished to cross the tru
pathway with the pat pathway that leads to patellamides.
Patellamides are not prenylated, and instead Ser and Thr
residues are cyclized to yield oxazoline residues.5,39,40 More-
over, often 2 thiazole residues exist in the pat products, instead
of 1 thiazoline as found in all known tru pathway relatives. The
genetic and biochemical basis of these differences have been
thoroughly established. We have been very interested in
determining the “portability” of enzymes; that is, can individual
RP enzymes be moved from one pathway to another? As a first
step to establish this fact, we cloned patellamide precursor
peptides that would normally yield the compounds ulithiacy-
clamide and patellamide C into the tru pathway background, to
give derivatives 21 and 22. 21 could not be produced, but 22
was successfully synthesized and contained 2 thiazoline
residues, the first time this modification has been reported in
tru derivatives. Both Thr residues were prenylated, rather than
heterocyclic as they would be in the natural product.
This report represents a significant expansion of the toolkit
available for directed, posttranslational modification of peptides
in living cells. Additionally, it provides the first technical
guidelines for performing complex manipulations with multi-
step RP pathways. Ultimately, we hope to improve control over
RP processing for directed synthetic biology of fine chemicals
and pharmaceuticals. This technology has numerous possible
applications, including supply of marine natural products and
improvement of anticancer properties of cyanobactins. More
importantly, such technology allows simple genetic engineering
tools to be applied to creation of wholly new drug motifs that
combine the advantages of peptide technology and synthetic
chemistry. For example, intein-circularized and phage display
libraries encode an enormous sequence diversity which can be
used to attack diverse biological targets,40 but the resulting
compounds are generally not drugs because of poor
pharmacological properties. The addition of many posttransla-
tional modifications promises to afford the same sequence
diversity, but with products that are more “drug-like”. Here, we
use the multistep cyanobactin pathway to explore the chemistry
that necessarily underlies these downstream applications.
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Materials and Methods 
Plasmids. ptru-SD1 was obtained from Symbion Discovery, Inc., in which the tru operon 
is controlled by lac. This vector performs identically to the previously reported TOPO-
tru, except that yield is improved. ptruE is derived from the previously reported pRSF-
true2 vector in which the TruE peptide is present in the pRSF vector backbone and TruE 
expression is controlled by lac.1 Restriction sites were introduced so that the second 
cassette of TruE2 could be replaced with desired variants. Top strand and bottom strand 
oligonucleotides encoding the desired cyanobactin variant were synthesized at the 
University of Utah Peptide Core Facility. The two strands were annealed ligated to ptruE 
digested with the corresponding restriction enzymes. T4 ligase (NEB) was used for 
cloning and E. coli TOP10 (Invitrogen) was used for the propagation of the plasmids. All 
constructs were verified by DNA sequencing. Using this conventional cloning method, 
ptruE-X1-ptruEX18 and ptruE-amber1 and ptruE-amber2 were constructed and verified 
by sequencing. These vectors are identical to previously reported pRSF-true2,1 except 
that the second cassette encodes the new cyanobactin variant.  
 
Expression of cyanobactin variants. ptru-SD1 and ptruE wild type or mutant vectors were 
co-transformed into Top10 E. coli cells (Invitrogen) following the manufacturer’s 
protocol and plated on LB agar plates supplemented with ampicillin (50 µg ml-1) and 
kanamycin (25 µg ml-1). Because expression from individual colonies is variable,1 for 
each mutant five to ten colonies were picked and grown overnight in 2xYT broth (5 ml). 
These seed cultures were pooled, and pooled broth (1 ml) was inoculated into 2xYT broth 
(100 ml) in a 250 ml flask. All 2xYT media contained ampicillin (50 µg ml-1), kanamycin 
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(25 µg ml-1), and a proprietary Symbion Mix that slightly improves yield but does not 
affect lac expression. The cells were cultivated for five days at 30 o C and 200 rpm, after 
which they were collected by centrifugation at 3320 x g  for 20 minutes. The cell pellet 
was washed with NaCl (100 mM) and extracted by sonication in methanol (75 ml) for 30 
minutes. The suspension was filtered, Diaion HP20 (5% v/v) was added to the filtrate, 
and the mixture was dried under vacuum to remove most of the methanol. The resin was 
transferred into vac elut cartridges (Varian) and washed with water, followed by a step 
gradient of methanol (25%, 50%, 100%) in water. The 100% methanol fraction was dried 
under vacuum and re-suspended in methanol (500 µl). An aliquot (50 µl) of this extract 
was passed through a small plug of end-capped C18 resin and analyzed by HPLC-ESI-MS 
using a Waters Micromass ZQ mass spectrometer and a Phenomenex C18 column (10 cm 
x 4.6 mm, 5µm). A linear gradient was employed at 0.2 ml min-1, from 10-100% 
acetonitrile in water (0.1% formic acid) over 20 minutes, followed by 15 minutes at 
100% acetonitrile. 
 
Co-expression of truE with amber suppressor tRNA/aaRS. Seven pRSF-TruE constructs 
containing all six possible amber stop codon mutants in the TVPTLC sequence and the 
wild type (WT) sequence were independently co-transformed with pEVOL-pAcF 
(incorporates p-acetylphenylalanine in response to the amber stop codon) in BL21(DE3) 
cells. Single colonies were picked for expression in LB media containing kanamycin (25 
µg ml-1), and chloramphenicol (25 µg ml-1) and grown overnight.  Cultures (250 ml) were 
grown to OD600=0.8 and induced with IPTG (1 mM) and arabinose (0.02%) and 
supplemented with pAcF (1 mM).  One culture of the pRSF-WT variant was not induced 
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with IPTG (indicated as uninduced in Figure S3).  After 12 hours, cultures were pelleted, 
lysed in Bugbuster cell lysis reagent (5 ml, Novagen), and purified using Ni-NTA resin 
(0.25 ml, Qiagen) following protocols in the Qiagen protein purification handbook for 
native purification.  Eluents were concentrated 5-fold before loading onto a 4-20% SDS-
PAGE gel (Novagen) with DTT (20 mM).  The gel was stained with a solution of 
Coomassie Blue R-250 (0.25%, Sigma) and washed before imaging.  The presence of 
full-length TruE protein in constructs containing an amber mutation indicated successful 
incorporation of the pAcF unnatural amino acid.    
 
In vivo synthesis of cyanobactins with non-protein amino acids. ptru-SD1 (Symbion 
Discovery, Inc.), ptruE-amber, and pEVOL-pCNF containing the amber suppresor 
tRNA/aaRS were co-transformed in Top10 E. coli cells following the manufacturer’s 
protocol and plated on LB agar plates supplemented with ampicillin (50 µg ml-1), 
kanamycin (25 µg ml-1), and chloramphenicol (25 µg ml-1). The resulting clones were 
treated as described in Expression of cyanobactin variants, except that chloramphenicol 
(12.5 µg ml-1) and non-proteinogenic amino acids (Chemimpex; 2 mM) were also added 
to the culture broth.  
 
To optimize induction, experiments were run as described above, except that growth was 
monitored until OD600=0.8, at which time L-arabinose was added at varying 
concentrations (0%, 2x10-4%, 2x10-3%, 2x10-2%, 2x10-1%). Expression using pEVOL 
was optimized using p-chloro-L-phenylanine (p-ClF) (2mM), which was added in 
batches. At inoculation, p-ClF was added to 0.7 mM and growth was monitored until 
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OD600=0.8 at which time L-arabinose and p-ClF (1.3 mM) were added. Later, this batch 
addition was found not to make a difference, so that exogenous amino acids (2 mM) were 
subsequently added upon inoculation. 
Characterization of fermentation products. Fractions containing new and known 
cyanobactin derivatives were partially purified using HP20 and C18 resins, as described 
above, and then analyzed by HPLC FT-ICR-ESI-MS at the University of Utah Mass 
Spectrometry Core Facility using a LTQ-FT (ThermoElectron), with MS/MS using 
collision induced dissociation (Table S2 and Figure S4). 
 
 Preparative fermentation of TVPT-pClF-C (11) and TSIASFC (15). Seed cultures were 
used to inoculate 2xYT broth (10 l) containing additives as above in a 14 l fermentor 
(Bioflo 110, New Brunswick Scientific). Fermentation was performed over five days at 
30 oC and 200 rpm, after which the cells were collected by centrifugation at 4424 x g and 
washed with NaCl (100 mM). The pellet was extracted with acetone (1.5 l). Diaion HP20 
(5% v/v) was added, and the slurry was dried under vacuum. The resin was then washed 
extensively with water, followed by 40% acetone. Finally, an extract enriched with 
desired compounds was obtained by elution with acetone (500 ml). The vacuum-dried 
acetone extract was fractionated by flash chromatography on silica gel (50 g, 230-400 
mesh) pre-equilibrated in 9:1 hexane: ethyl acetate. A step gradient was employed 
consisting of the following solvents: 1) 9:1 hexane: ethyl acetate (100 ml); 2) 1:1 hexane: 
ethyl acetate (100 ml); 3) ethyl acetate (150 ml); 4) 10:1 dichloromethane: methanol (200 
ml); 5) 5:1 dichloromethane: methanol (200 ml). Fractions 3 and 4, containing 
cyanobactin derivatives, were further purified by HPLC on a Hitachi LaChrom Elite 
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system using two rounds of chromatography. The first employed a gradient of 35-100 % 
acetonitrile (aq) over 40 minutes (2 ml min-1) on a Supelco HS Discovery (25 cm x 10 
mm, 5 µm) C18 HPLC column. The second used 72 % acetonitrile (aq; 1 ml min-1) on a 
Phenomenex Gemini (25 cm x 4.6 mm, 5µm) C18 HPLC column. NMR data were 
obtained using a Varian INOVA 600 (1H 600 MHz). For spectral data, see Figures S5 and 
S6. 
 
Yield determination.Yield of purified products could be determined by the usual methods, 
but we also sought more accurate determination using spectroscopic techniques, detailed 
below. 
 
Quantification by NMR. 1H NMR quantification was performed on a Varian INOVA 
digital 500 MHz NMR spectrometer at 25 o C. Quantification was performed using an 
external standard, 1,4-dinitrobenzene (DNB) (Sigma-Aldrich), following a previously 
validated method.2 The standard 1 and different dilutions of DNB were prepared in 
DMSO-d6 (Cambridge Isotopes) (120 mL) in identical,  vacuum-dried NMR tubes 
(3mm). All samples were treated identically by placing into the probe and tuning and 
matching to identical values. All 1H NMR experiments were run using the same 
conditions, with repeated single 90o  pulse sequence, D1(5T1) of 4s, and 512 scans  as 
determined for appropriate signal averaging. Calibration of the p90o  pulse length for each 
samples was done by determination of the null (360o) pulse length (pw=pw/4). T1 




A two-fold dilution series of DNB (6 samples from 0.4 to 0.0125 mg) was prepared in 
DMSO-d6 from a stock solution (34 mg/mL). The singlet signal at 8.4 ppm corresponding 
to four equivalent protons of DNB was integrated and used to generate a standard curve 
under various conditions (Figure S1). The 1H NMR spectrum of 1 was measured under 
identical conditions, and well-separated NH (d 7.4X ppm) and methyl (d 0.73 ppm) 
signals were integrated and compared to the standard curve of DNB (Figure S1). Under 
several different conditions, reproducible values were obtained using this method, which 
met the previously described accuracy level.2 
 
Quantification by HPLC-MS. The quantified NMR sample measured above was used 
directly from the NMR tube to generate highly accurate standards for MS. To generate a 
standard curve, a serial dilution of known concentrations of 1 (five different 
concentrations, from 0.26 to 0.032 mg in 40 mL MeOH) was used (Figure S2). This 
curve was generated both in pure MeOH and by adding the diluted standard to crude of 
the E. coli expression constructs reported above. Samples were then run under the LC-
MS conditions described above. The area under the curve was determined by obtaining 
the spectrum corresponding to 1 over its ~2.5 min elution time, then multiplying this time 
by the average signal intensity at m/z = 733.5 over that time. Analysis was performed in 
duplicate and the integrations for each point were averaged. A plot of area vs. 
concentration was generated, indicating that the signal response to concentration was 
linear and that 1 provided a robust internal standard over the concentration range being 
measured. The resulting linear equation was used to calculate the concentrations of the 
recombinant and standard compounds (Figure S2).   
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Figure S1. A. Stacked 1H-NMR spectra and integration values of 1,4-dinitrobenzene at 













Table S1. Calculated and observed masses for compounds synthesized in E. coli. Prenylation 
state varied, and often derivatives were found that were not completely prenylated. 









!"#!$%&'=(& )*+,-.+)& )*+,-...& /0/,.+& 1/.,*/&
!"#!$%&'=(&'2(3& 1/.,.14+& 1/.,.)5+& & /0/,.+&
$6778%&';(& 1.4,..*.& 1.4,..*/& 9& 9&
!!6!#%&':(& )1.,--**& )1.,--.+& 1*),*+& 14/,*5&
!!6!#%&':(&'2(& 14/,.)41& 14/,.05+& //4,*5& 1*),*5&
!67!9:;9%&'>(&'2(& ))),*1-5& ))),*1--& 9& )++,+/&
!67!9<%=89%&'89(& 05+,.))5& 05+,.)4.& 11/,*0& )..,*5&
!67!9<%=89%&'89(&'2(& )..,.+--& )..,.+/0& & 11/,*)&
!67!9<>?@89%&'88(&'2(& )*4,.1-5& )*4,.1/-& 9& 11+,.5&
!67!9<A.89%&'8?(&'2(& )-5,./-0& )-5,.//4& 9& 1)*,*)&
!B$#7"%&'8@(& 05-,-100& 05-,-144& 110,.5& ).1,.-&
!B$#7"%&'8@(&'2(& ).1,-51*& ).1,-51/& 9& 110,.5&
!B$#B8%&'8=(& 041,-4/5& 9& 9& 9&
!B$#B8%&'8=(&'2(& 0*0,-.*-& 0*0,-.-+& 14*,*1& )15,*+&
!B$#79<:;89%'8<('22(& )05,*0/5& )05,*.00& 9& 9&
!"767!6%&'8>(& 4*4,//*0& 9& 9& 9&
!"767!6%&'8>(&'2(& 01+,-45*& 01+,-4+-& 9& )4.,.0&
!6767B8%&'?9(& 4-4,/*+/& 4-4,/**0& 0+.,-+& 00+,-/&
!6767B8%&'?9(&'2(& 00+,-/04& 00+,-15.& 9& 0+.,-.&
6!#%$!8%&'??(& 4.4,-0.5& 4.4,-0.*& 05.,.*& 0)+,*)&
6!#%$!8%&'??(&'2(& 0)+,-*5/& 0)+,-**/& 9& 05.,..&!
a) all masses observed with +/- 2 ppm error 
b) (i) indicates compounds produced with 1 less prenyl group 
c) - C10H16  indicates loss of 2 prenyl groups (MS/MS) 




Figure S3. Co-expression of precursor peptide constructs with pEVOL-pAcF where X 
indicates the position of the amber stop codon in the truE primary amino acid 
sequence.  The wild type (WT) sequence contains no amber stop codon (sequence 









































Figure S4.  
A1   TLATIC (4) chromatogram 
A2   TLATIC (4) spectrum 
A3   TLATIC (4) MS-MS spectrum 
B1   TLATIC (4) (i) chromatogram 
B2   TLATIC (4) (i) spectrum 
B3   TLATIC (4) (i) MS-MS spectrum 
C1   IVPPFC (5) chromatogram 
C2   IVPPFC (5) spectrum 
C3   IVPPFC (5) MS-MS %&'()*+,!
D1   TTVTAC (7) chromatogram 
D2   TTVTAC (7) spectrum 
D3   TTVTAC (7) MS-MS %&'()*+,!
E1   TTVTAC (7) (i) chromatogram 
E2   TTVTAC (7) (i) spectrum 
E3   TTVTAC (7) (i) MS-MS %&'()*+,!
F1   TVPT-pBrF-C (9) (i) chromatogram 
F2   TVPT-pBrF-C (9) (i) spectrum 
F3   TVPT-pBrF-C (9) (i) MS-MS %&'()*+, 
G1   TVPT-pClF-C (10) chromatogram 
G2   TVPT-pClF-C (10) spectrum 
G3   TVPT-pClF-C (10) MS-MS %&'()*+, 
H1   TVPT-pClF-C (10) (i) chromatogram 
H2   TVPT-pClF-C (10) (i) spectrum 
H3   TVPT-pClF-C (10) (i) MS-MS %&'()*+, 
I1   TVPT-pOMeF-C (11) (i) chromatogram 
I2   TVPT-pOMeF-C (11) (i) spectrum 
I3   TVPT-pOMeF-C (11) (i) MS-MS %&'()*+, 
J1   TVPT-pN3F-C (12) (i) chromatogram 
J2   TVPT-pN3F-C (12) (i) spectrum 
J3   TVPT-pN3F-C (12) (i) MS-MS %&'()*+, 
K1   TSIAPLC (13) chromatogram 
K2   TSIAPLC (13) spectrum 
K3   TSIAPLC (13)  MS-MS %&'()*+, 
L1   TSIAPLC (13) (i) chromatogram 
L2   TSIAPLC (13) (i) spectrum 
L3   TSIAPLC (13) (i) MS-MS spectrum and assignments 
M1  TSIASFC (14)  chromatogram 
M2  TSIASFC (14)  spectrum 
M3  TSIASFC (14)  MS-MS %&'()*+, 
N1  TSIASFC (14) (i) chromatogram 
N2  TSIASFC (14) (i) spectrum 













O1   TSIAS-pBrFC (18) (i) chromatogram 
O2   TSIAS-pBrFC (18) (i) spectrum 
O3   TSIAS-pBrFC (18) (i) MS-MS %&'()*+, 
P1    TLPVPTVC (19) chromatogram 
P2    TLPVPTVC (19) spectrum 
P3    TLPVPTVC (19) MS-MS %&'()*+, 
Q1    TLPVPTVC (20) (i) chromatogram 
Q2    TLPVPTVC (20) (i) spectrum 
Q3    TLPVPTVC (20) (i) MS-MS %&'()*+, 
R1    TVPVPSFC (21) (i) chromatogram 
R2    TVPVPSFC (21) (i) spectrum 
R3    TVPVPSFC (21) (i) MS-MS %&'()*+, 
S1   VTACITFC (22) chromatogram 
S2   VTACITFC (22) spectrum 
S3   VTACITFC (22) MS-MS %&'()*+, 
T1   VTACITFC (22) (i) chromatogram 
T2   VTACITFC (22) (i) spectrum 






S4. A1. LC-FT-ICR %&'&()&*!+,-!(./,01),2/10!3,/!TLATIC (4)!
A2. LC-FT-ICR spectrum of TLATIC (4) 
A3. MS-MS spectrum of TLATIC (4) 
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S4. B1. LC-FT-ICR %&'&()&*!+,-!(./,01),2/10!3,/!TLATIC (4) (i)!
B2. LC-FT-ICR spectrum of TLATIC (4) (i) 
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!!"#$"%&'()*+,-&)*.,+/'(&!0'1233%46W$0"$=880D ;&7 !><0>=?$<0D 927 !D LM7 !<C$N?
&7 9G,+*X,6TS,KF+I@6:Q$6C?><?#6A$0"$=880DB


























































































































S4. C1. LC-FT-ICR %&'&()&*!+,-!(./,01),2/10!3,/!IVPPFC (5)!
C2. LC-FT-ICR spectrum of IVPPFC (5) 
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S4. D1. LC-FT-ICR .(+(/0(1!23)!/4'356037'65!83'!TTVTAC (7)!
D2. LC-FT-ICR spectrum of TTVTAC (7) 
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S4. E1. LC-FT-ICR %&'&()&*!+,-!(./,01),2/10!3,/!TTVTAC (7) (i)!
E2. LC-FT-ICR spectrum of TTVTAC (7) (i) 
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S4. F1. LC-FT-ICR ,(+(-.(/!01)!-2'134.15'43!61'!TVPT-pBrF-C (9) (i)!
F2. LC-FT-ICR spectrum of TVPT-pBrF-C (9) (i) 
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S4. G1. LC-FT-ICR ,(+(-.(/!01)!-2'134.15'43!61'!TVPT-pClF-C (10)!
G2. LC-FT-ICR spectrum of TVPT-pClF-C (10) 
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S4. H1. LC-FT-ICR $%&%'(%)!*+,!'-.+/0(+1.0/!2+.!TVPT-pClF-C (10) (i)!
H2. LC-FT-ICR spectrum of TVPT-pClF-C (10) (i) 
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S4. I1. LC-FT-ICR ,(+(-.(/!01)!-2'134.15'43!61'!TVPT-pOMeF-C (11) (i)!
I2. LC-FT-ICR spectrum of TVPT-pOMeF-C (11) (i) 
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S4. J1. LC-FT-ICR ,(+(-.(/!01)!-2'134.15'43!61'!TVPT-pN3F-C (12) (i)!
J2. LC-FT-ICR spectrum of TVPT-pN3F-C (12) (i) 
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S4. Q1. LC-FT-ICR -),)./)0!12*!.3(245/26(54!72(!TVPVPSFC (20)!
Q2. LC-FT-ICR spectrum of TVPVPSFC (20) 
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S4. R1. LC-FT-ICR %&'&()&*!+,-!(./,01),2/10!3,/!TVPVPSFC (20) (i)!
R2. LC-FT-ICR spectrum of TVPVPSFC (20) (i) 
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S4. S1. LC-FT-ICR ,'*'-.'/!01(!-2&134.15&43!61&!VTACITFC (22)!
S2. LC-FT-ICR spectrum of VTACITFC (22) 
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S4. T1. LC-FT-ICR %&'&()&*!+,-!(./,01),2/10!3,/!VTACITFC (22) (i)!
T2. LC-FT-ICR spectrum of VTACITFC (22) (i) 




















 Figure S5. 




















 Figure S5.  



























































 We set out to address the two outstanding problems in natural products drug 
discovery: the variability in occurrence and supply of natural products. Both of these 
challenges create a significant hindrance to the development of natural products into 
useful drugs. Although geographical and sample-to-sample variability in occurrence can 
occur in terrestrial natural products, 1 it can be particularly widespread for those natural 
products derived from marine organisms. Several reasons may explain variability of 
occurrence for marine natural products, such the complexity of ocean habitats 2,3 (local 
predation, competition, flux of microbes from seawater) as well as difficulties assigning 
species among heteromorphic organisms such as sponges. 4,5 Answering the question of 
‘who makes what, when, and why?’ is therefore highly pertinent to understanding the 
distribution of natural products and their potential. 
 There is increasing evidence that symbiotic bacteria are the actual producers of 
most marine invertebrate-derived NPs. 6-9 We thus proposed that symbiotic bacteria are 
central to distribution of marine natural products.  Further, we proposed that the factors 
that control symbiosis in turn control the distribution of natural products. Piece by piece, 
this hypothesis has been addressed in individual studies of chemical symbiosis. We asked 
if there are global patterns and what they would mean for drug discovery – global in this 
sense means examining all symbionts and chemicals within different animals and the 
changes in their distribution across time, location, and hosts. It was therefore critical that 
we use sequencing platforms capable of identifying thousands of bacteria in each sample.  
This approach allowed us to compare their general characteristics as a community to the 
other variables that were being tested. Statistical methods that are independent of 
! "#"!
metabolite identity were also critical for the overall analysis of chemistry between many 
samples.  
 We found that in ascidians, the hosts generally select their symbionts and 
secondary metabolites. In known cases, the symbionts that are natural product producers 
are the most abundant components of the microbiome. This is an important finding in the 
era of genomics-based natural product discovery, not just in ascidians but also in other 
marine invertebrates. Marine invertebrates are microbial hotspots, 10,11 containing 
hundreds or thousands of different species of bacteria. Here we show that in mining for 
microbial producers of natural products, efforts should be focused on the most abundant 
microbes in the composition.  Studying the latitudinal influence of geography to the 
symbionts and chemistry was very important as it revealed that the selection pressure 
between these regions could influence chemistry and symbiosis in imbalanced ways. 
While the symbionts generally maintained host specificity, the potency of secondary 
metabolites increased in tropical samples. Therefore, within the limits of our sampling 
and analysis, symbiosis is generally host-specific while secondary metabolism can be 
location specific when there are large biogeographical divides such as water temperature 
and species diversity.  
 While it is tempting to generalize our results to a broader section of marine 
invertebrates, their symbionts, and associated metabolites, it is important to reiterate the 
limits of our data.  In particular, our tests on the potency of extracts were limited to a 
select few strains, which may not capture ecologically relevant activities of the extracts 
from temperate ascidians. Additionally, since almost none of the chemistry can be 
identified from the temperate ascidians in the database collections, it is difficult to say 
! "#$!
precisely what differences in chemistry exist between closely related species in temperate 
and tropical regions. In this respect, methods that can reveal structural relatedness 
without dependence on complete identification and isolation of compounds, such as 
molecular networking, will be useful in future studies. 12 
 To address the supply of symbiotic natural products, we used the heterologous 
expression of cyanobactins as a model case. Cyanobactin pathways are not only 
amenable to library generation; they are also amenable to metabolic engineering, 
specifically through precursor supply and simple fermentation optimization. 
Serendipitously, we discovered that increasing the precursor DMAPP improved 
cyanobactin production, in a manner that is independent of compound prenylation. The 
scope of this effect is of great interest in that it might be applicable to other heterologous 
systems such as to other RiPPs, or other natural product pathways in general. The ability 
to supply cyanobactins will now allow further practical investigations on their chemistry 
and biology. Indeed this method allowed us to uncover the first activity for patellin 2 
using a high content phenotypic assay. This opens the possibility of finding more 
activities for ‘orphan’ cyanobactins and may lead to a clearer picture of their ecological 
roles. We further demonstrated the capacity of cyanobactin pathways to generate unusual 
derivatives containing nonproteinogenic amino acids. By incorporating unnatural amino 
acids to the cyanobactin backbone, we successfully combined the structural complexity 
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